# Medical Question & Answer

**Sample ID**: 8deee79b-5b15-1a6e-70ed-b1cb906a5033
**Dataset Index**: 72410

---

## Question

How long do you treat Kendall's oxytoco

---

## Answer

> Let's see… What do we have here? The user is asking how long to treat "Kendall's oxytoco". Let's break this down step-by-step. First, I need to think about what "Kendall's oxytoco" actually refers to in standard obstetric terminology. Then, I should verify whether the question targets induction versus augmentation and whether it implies a specific protocol. Next, I will extract the highest-quality guideline recommendations on duration thresholds, including when to call an induction failed and when to continue augmentation. After that, I should review randomized and meta-analytic data on stopping oxytocin in the active phase. Finally, I will synthesize a practical, safety-focused answer with clear time frames and monitoring checkpoints, and I will double-check for any exceptions like TOLAC or special populations before concluding.

> Let me first confirm the terminology, because "Kendall's oxytoco" does not map to a standard obstetric term. Wait, let me verify whether this is a misstatement for "oxytocin" used for induction or augmentation of labor, which is commonly titrated intravenously with institution-specific protocols; given the context and the provided references, I will proceed assuming the user is asking about the duration of oxytocin treatment during labor induction or augmentation, and I will anchor to contemporary guidelines and trials to answer how long to continue oxytocin in different scenarios [^0878b48a] [^8c919e1e] [^7db8960e].

> Next, I should clarify the clinical frame: induction of labor versus augmentation of labor are related but distinct. Induction starts contractions when labor has not begun, whereas augmentation accelerates existing contractions that are inadequate. Hold on, I should verify that the duration advice differs slightly between these contexts, so I will keep them separate as I proceed and cite guideline-based thresholds for each [^0878b48a] [^8c919e1e].

> For induction of labor, I need to check the threshold for calling an induction failed. ACOG advises that if maternal and fetal status remain reassuring, cesarean delivery for failed induction should be avoided by recommending oxytocin for at least 12–18 hours after membrane rupture before deeming induction unsuccessful, with continuation beyond 18 hours individualized; importantly, more than 96% of nulliparous patients reached active labor by 15 hours in a large cohort, which helps set expectations for duration in latent-phase induction [^7db8960e]. Let me reconsider whether any other guideline contradicts this; WHO and EAPM emphasize confirming delay before oxytocin and using clinical judgment, but they do not specify a hard "failed induction" time window, reinforcing that ACOG's 12–18 hour framework is the most explicit duration threshold available here [^69c3e5db] [^7dc412fb].

> For augmentation of labor, I should confirm how long to continue oxytocin once adequate contractions are established. The European Association of Perinatal Medicine recommends continuing oxytocin augmentation for at least 4 hours with adequate contractions before declaring arrest and proceeding to cesarean, provided maternal and fetal conditions remain good; this applies to the first stage of labor in nulliparous patients with arrested or protracted labor [^8c919e1e]. Hold on, I should verify that this aligns with broader guidance; ACOG similarly emphasizes allowing adequate time with adequate contractions before diagnosing arrest, supporting a minimum of several hours of augmentation before moving to operative delivery [^faafe5fb].

> Now, I will examine whether stopping oxytocin in the active phase changes outcomes, because that affects "how long" to treat. Multiple randomized trials and meta-analyses show that discontinuing oxytocin once the active phase is established reduces uterine tachysystole and nonreassuring fetal heart rate patterns and may reduce cesarean delivery, albeit with a modest increase in active-phase duration; pooled analyses suggest roughly a 20% reduction in cesarean with discontinuation, though certainty varies and some sensitivity analyses attenuate the effect, so I should present this as a reasonable strategy rather than a mandate [^9705f84b] [^390f224d] [^5a2d2355]. Wait, let me verify the magnitude; the ACOG summary reports cesarean 9.3% vs 14.7% with discontinuation, with a mean 27–30 minute increase in active labor, which is clinically acceptable in many cases [^9705f84b] [^390f224d].

> I should also consider dosing cadence and escalation intervals, because "how long" is influenced by how fast we titrate. Low-dose regimens typically start at 0.5–2 mU/min with 1–2 mU/min increments every 15–40 minutes, whereas high-dose regimens start at 4 or more mU/min with 3–6 mU/min increments; both are acceptable, but higher-dose approaches increase tachysystole without consistent reductions in cesarean, so I need to ensure we titrate to adequate contractions rather than a fixed duration or maximum dose [^0878b48a] [^0e2199c0]. Hold on, I should verify the safety ceiling; many protocols cap around 20–32 mU/min, but ACOG notes no established maximum, so individualized titration with close monitoring is key rather than chasing a dose target [^0878b48a] [^03d64c00].

> Let me synthesize practical duration guidance by scenario, and I will double-check each element against guidelines. For induction, plan to continue oxytocin for at least 12–18 hours after membrane rupture before calling it failed, recognizing most will enter active labor within 15 hours; extend beyond 18 hours only if progress is ongoing and maternal–fetal status is reassuring, and consider discontinuation once active labor is established to reduce tachysystole and cesarean risk, with readiness to restart if arrest recurs [^7db8960e] [^9705f84b]. For augmentation, continue for at least 4 hours with adequate contractions before diagnosing arrest, and reassess maternal–fetal status regularly; if contractions are adequate and there is no cervical change, proceed to cesarean rather than escalating indefinitely [^8c919e1e] [^faafe5fb]. Throughout, I need to ensure contractions are adequate (about 3–5 per 10 minutes or ≥ 200 Montevideo units) and stop or reduce oxytocin for tachysystole or fetal compromise, which resets the clock on any "duration" threshold [^0878b48a] [^ebefaa4f].

> But wait, what if the clinical context is special, like TOLAC or preterm gestation. I should confirm that TOLAC does not have a different minimum duration rule; ACOG allows oxytocin augmentation in TOLAC with awareness of a dose–response relationship to uterine rupture risk, so the same principle of adequate time with adequate contractions applies, with heightened vigilance and individualized dosing rather than a different duration threshold [^33076725]. For preterm induction or augmentation, evidence is more limited, so duration decisions should be individualized and guided by maternal–fetal tolerance and local protocols rather than fixed time windows [^notfound].

> In summary, I need to ensure the answer is precise and safety-focused. For induction, treat with oxytocin for at least 12–18 hours after membrane rupture before declaring failure, and consider stopping once active labor is established to reduce adverse effects, with readiness to restart if arrest occurs. For augmentation, treat for at least 4 hours with adequate contractions before diagnosing arrest. Throughout, titrate to a physiologic contraction pattern, monitor continuously, and stop for hyperstimulation or fetal compromise, adjusting the plan based on maternal–fetal status and patient preferences [^7db8960e] [^9705f84b] [^8c919e1e] [^0878b48a].

---

Oxytocin is continued until **active labor is established** (about 5–6 cm dilation with regular contractions) [^9705f84b], then **stopped or reduced** to lower tachysystole and cesarean risk [^390f224d] [^9705f84b]. If labor stalls, continue for at least 4 hours with adequate contractions before declaring arrest and proceeding to cesarean [^8c919e1e]. For induction, continue until active labor or for 12–18 hours after membrane rupture before calling it failed [^7db8960e]. Always titrate to the lowest effective dose and stop for hyperstimulation or fetal distress [^ebefaa4f].

---

## Indications for oxytocin use

Oxytocin is used for **induction of labor** when labor has not started spontaneously or when there is a medical indication to deliver the baby [^0878b48a], and for **augmentation of labor** when labor has started but progress is slow due to inadequate uterine contractions [^2a4675bb].

---

## Recommended duration of oxytocin treatment

The duration of oxytocin treatment varies depending on the clinical scenario:

| **Clinical scenario** | **Recommended duration** | **Evidence level** |
|-|-|-|
| Induction of labor | - Continue until active labor is established (approximately 5–6 cm cervical dilation with regular contractions) [^9705f84b] <br/> - If active labor is not established within 12–18 hours after membrane rupture, consider failed induction and reassess [^7db8960e] | High |
| Augmentation of labor | - Continue until active labor is established or until adequate uterine activity is achieved (3–5 contractions per 10 minutes) [^2bb46ba4] <br/> - If labor progress stalls, continue for at least 4 hours with adequate contractions before declaring arrest and proceeding to cesarean delivery [^8c919e1e] | High |
| Active phase of labor | Consider discontinuing or reducing oxytocin once active labor is established to reduce the risk of uterine tachysystole and cesarean delivery [^9705f84b] [^390f224d] | High |

---

## Factors influencing duration of oxytocin treatment

Several factors influence how long oxytocin should be continued:

- **Maternal factors**: Parity, age, body mass index (BMI), and medical conditions such as hypertension or diabetes may influence oxytocin requirements and duration of treatment [^aa1901f9].
- **Fetal factors**: Gestational age, fetal position, and fetal well-being (assessed by continuous fetal monitoring) are critical in determining the duration of oxytocin treatment [^ebefaa4f].
- **Labor progression**: The rate of cervical dilation, descent of the fetal head, and strength and frequency of uterine contractions guide the continuation or discontinuation of oxytocin [^0878b48a].
- **Clinical judgment**: Individualized assessment by the healthcare provider is essential to determine the appropriate duration of oxytocin treatment [^7dc412fb].

---

## Risks associated with prolonged oxytocin use

Prolonged oxytocin administration carries potential risks, including:

- **Uterine hyperstimulation**: Excessive uterine activity can lead to fetal hypoxia and increase the risk of cesarean delivery [^390f224d].
- **Fetal distress**: Prolonged oxytocin use can cause changes in fetal heart rate patterns, necessitating immediate intervention [^ebefaa4f].
- **Postpartum hemorrhage**: Prolonged oxytocin exposure may lead to uterine muscle fatigue, increasing the risk of postpartum hemorrhage [^03d64c00].
- **Water intoxication**: Prolonged high-dose oxytocin can cause hyponatremia due to its antidiuretic effect [^notfound].

---

## Clinical guidelines and recommendations

Major obstetric organizations provide the following recommendations:

- **ACOG**: Recommends either low-dose or high-dose oxytocin regimens for induction and augmentation of labor, with continuous monitoring of uterine activity and fetal heart rate. Oxytocin should be titrated to the lowest effective dose and discontinued if hyperstimulation or fetal distress occurs [^0878b48a] [^ebefaa4f].
- **WHO**: Recommends oxytocin for induction and augmentation of labor, emphasizing careful monitoring and individualized dosing based on maternal and fetal conditions [^2a4675bb].
- **EAPM**: Recommends continuing oxytocin augmentation for at least 4 hours with adequate contractions before declaring arrest and proceeding to cesarean delivery, provided maternal and fetal conditions remain favorable [^8c919e1e].

---

## Summary of recommendations

- **Induction of labor**: Continue oxytocin until active labor is established (approximately 5–6 cm cervical dilation with regular contractions). If active labor is not established within 12–18 hours after membrane rupture, consider failed induction and reassess [^7db8960e].
- **Augmentation of labor**: Continue oxytocin until active labor is established or until adequate uterine activity is achieved. If labor progress stalls, continue for at least 4 hours with adequate contractions before declaring arrest and proceeding to cesarean delivery [^8c919e1e].
- **Active phase of labor**: Consider discontinuing or reducing oxytocin once active labor is established to reduce the risk of uterine tachysystole and cesarean delivery [^9705f84b] [^390f224d].

---

The duration of oxytocin treatment varies with clinical context: continue until active labor or adequate contractions, typically 4–6 hours for augmentation and 12–18 hours for induction, then stop or reduce to mitigate tachysystole and cesarean risk [^8c919e1e] [^7db8960e] [^9705f84b].

---

## References

### European guidelines on management of arrested or protracted labor in nulliparous women [^7dc412fb]. European Journal of Obstetrics, Gynecology, and Reproductive Biology (2025). High credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, EAPM 2025 guidelines recommend to inform patients that there is no evidence regarding the beneficial effects of immediate (< 1 hour) or delayed administration of oxytocin after diagnosing arrested or protracted labor. Recognize that it might impact the duration of labor. Make decisions based on clinical judgment as well as the patient's values and preferences.

---

### High-dose versus low-dose oxytocin infusion regimens for induction of labour at term [^0e2199c0]. The Cochrane Database of Systematic Reviews (2014). Low credibility.

Background

When women require induction of labour, oxytocin is the most common agent used, delivered by an intravenous infusion titrated to uterine contraction strength and frequency. There is debate over the optimum dose regimen and how it impacts on maternal and fetal outcomes, particularly induction to birth interval, mode of birth, and rates of hyperstimulation. Current induction of labour regimens include both high- and low-dose regimens and are delivered by either continuous or pulsed infusions, with both linear and non-linear incremental increases in oxytocin dose. Whilst low-dose protocols bring on contractions safely, their potentially slow induction to birth interval may increase the chance of fetal infection and chorioamnionitis. Conversely, high-dose protocols may cause undue uterine hyperstimulation and fetal distress.

Objectives

To determine the effectiveness and safety of high- versus low-dose oxytocin for induction of labour at term

Search Methods

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 August 2014) and the reference lists of relevant papers.

Selection Criteria

Randomised controlled trials and quasi-randomised controlled trials that compared oxytocin protocol for induction of labour for women at term, where high-dose oxytocin is at least 100 mU oxytocin in the first 40 minutes, with increments delivering at least 600 mU in the first two hours, compared with low-dose oxytocin, defined as less than 100 mU oxytocin in the first 40 minutes, and increments delivering less than 600 mU total in the first two hours.

Data Collection and Analysis

Two review authors independently assessed study eligibility, extracted data and assessed the risk of bias of included studies. Data were checked for accuracy.

Main Results

We have included nine trials, involving 2391 women and their babies in this review. Trials were at a moderate to high risk of bias overall. Results of primary outcomes revealed no significant differences in rates of vaginal delivery not achieved within 24 hours (risk ratio (RR) 0.94, 95% confidence interval (CI) 0.78 to 1.14, two trials, 1339 women) or caesarean section (RR 0.96, 95% CI 0.81 to 1.14, eight trials, 2023 women). There was no difference in serious maternal morbidity or death (RR 1.24, 95% CI 0.55 to 2.82, one trial, 523 women), and no difference in serious neonatal morbidity or perinatal death (RR 0.84, 95% CI 0.23 to 3.12, one trial, 781 infants). Finally, no trials reported on the number of women who had uterine hyperstimulation with fetal heart rate changes. Results of secondary outcomes revealed no difference between time from induction to delivery (mean difference (MD) -0.90 hours, 95% CI -2.28 to +0.49 hours; five studies), uterine rupture (RR 3.10, 95% CI 0.50 to 19.33; three trials), epidural analgesia (RR 1.03, 95% CI 0.89 to 1.18; two trials), instrumental birth (RR 1.22, 95% CI 0.88 to 1.66; three trials), Apgar less than seven at five minutes (RR 1.25, 95% CI 0.77 to 2.01, five trials), perinatal death (RR 0.84, 95% CI 0.23 to 3.12; two trials), postpartum haemorrhage (RR 1.08, 95% CI 0.87 to 1.34; five trials), or endometritis (RR 1.35, 95% CI 0.53 to 3.43; three trials). Removal of high bias studies reveals a significant reduction of induction to delivery interval (MD -1.94 hours, 95% CI -0.99 to -2.89 hours, 489 women). A significant increase in hyperstimulation without specifying fetal heart rate changes was found in the high-dose group (RR 1.86, 95% CI 1.55 to 2.25). No other secondary outcomes were reported: unchanged/unfavourable cervix after 12 to 24 hours, meconium-stained liquor, neonatal intensive care unit admission, neonatal encephalopathy, disability in childhood, other maternal side-effects (nausea, vomiting, diarrhoea), maternal antibiotic use, maternal satisfaction, neonatal infection and neonatal antibiotic use.

Authors' Conclusions

The findings of our review do not provide evidence that high-dose oxytocin increases either vaginal delivery within 24 hours or the caesarean section rate. There is no significant decrease in induction to delivery time at meta-analysis but these results may be confounded by poor quality trials. High-dose oxytocin was shown to increase the rate of uterine hyperstimulation but the effects of this are not clear. The conclusions here are specific to the definitions used in this review. Further trials evaluating the effects of high-dose regimens of oxytocin for induction of labour should consider all important maternal and infant outcomes.

---

### WHO recommendations for augmentation of labour [^2a4675bb]. Geneva: World Health Organization (2014). Medium credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, WHO 2014 guidelines recommend to administer oxytocin, alone or with amniotomy, for treatment of confirmed delay in labor.

---

### High-versus low-dose oxytocin for augmentation or induction of labor [^abec588e]. The Annals of Pharmacotherapy (2005). Low credibility.

Objective

To compare the use of high- and low-dose oxytocin for augmentation or induction of labor.

Data Sources

Clinical trials were accessed through MEDLINE (1966-November 2003). Published literature relevant to the use of oxytocin for augmentation or induction of labor was evaluated.

Study Selection and Data Extraction

Articles identified from the data sources were evaluated and included if they were clinical trials comparing high-versus low-dose oxytocin for augmentation or induction of labor.

Data Synthesis

Oxytocin is a treatment of choice for augmentation and induction of labor; however, no consensus exists regarding optimal dosing. Relevant studies comparing high-dose (2–6 mU/min) and low-dose (1–2 mU/min) therapy for labor augmentation and induction were evaluated.

Conclusions

High-dose oxytocin decreases the time from admission to vaginal delivery, but does not appear to decrease the incidence of cesarean sections when compared with low-dose therapy.

---

### European guidelines on management of arrested or protracted labor in nulliparous women [^8c919e1e]. European Journal of Obstetrics, Gynecology, and Reproductive Biology (2025). High credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, EAPM 2025 guidelines recommend to consider continuing oxytocin augmentation in arrested or protracted labor during the first stage of labor for at least 4 hours with adequate contractions before deciding on a C-section, provided good fetal and maternal conditions.

---

### European guidelines on management of arrested or protracted labor in nulliparous women [^b18a34c5]. European Journal of Obstetrics, Gynecology, and Reproductive Biology (2025). High credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, EAPM 2025 guidelines recommend to consider administering a low-dose oxytocin regimen for labor augmentation in nulliparous patients at term with arrested or protracted labor.

---

### WHO recommendations for augmentation of labour [^98dd39c3]. Geneva: World Health Organization (2014). Medium credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, WHO 2014 guidelines recommend to do not use high starting and increment dosage regimens of oxytocin for labor augmentation.

---

### Prevention and management of postpartum hemorrhage… [^00a13808]. AAFP (2007). Low credibility.

30 Oxytocin is an effective first-line treatment for postpartum hemorrhage 31; 10 international units should be injected intramuscularly, or 20 IU in 1 L of saline may be infused at a rate of 250 mL per hour. As much as 500 mL can be infused over 10 minutes without complications.
10. Hematomas can present as pain or as a change in vital signs disproportionate to the amount of blood loss. Small hematomas can be managed with close observation. 41 Patients with persistent signs of volume loss despite fluid replacement, as well as those with large or enlarging hematomas, require incision and evacuation of the clot. 41 The involved area should be irrigated and the bleeding vessels ligated. In patients with diffuse oozing, a layered closure will help to secure hemostasis and eliminate dead space. 50One management option is to inject the umbilical vein with 20 mL of a solution of 0. 9 percent saline and 20 units of oxytocin.

This significantly reduces the need for manual removal of the placenta compared with injecting saline alone. 51Alternatively, physicians may proceed directly to manual removal of the placenta, using appropriate analgesia. If the tissue plane between the uterine wall and placenta cannot be developed through blunt dissection with the edge of the gloved hand, invasive placenta should be considered. 49The most common treatment for invasive placenta is hysterectomy. 49However, conservative management is sometimes successful. 53Women treated for a retained placenta must be observed for late sequelae, including infection and late postpartum bleeding. 52, 53. THROMBIN Coagulation disorders, a rare cause of post-partum hemorrhage, are unlikely to respond to the measures described above.

Evaluation should include a platelet count and measurement of prothrombin time, partial thromboplastin time, fibrinogen level, and fibrin split products. Management consists of treating the underlying disease process, supporting intravascular volume, serially evaluating coagulation status, and replacing appropriate blood components. Administration of recombinant factor VIIa or clot-promoting medications may be considered. 33, 54, 56.

---

### WHO recommendations for augmentation of labour [^69c3e5db]. Geneva: World Health Organization (2014). Medium credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, WHO 2014 guidelines recommend to do not administer IV oxytocin for augmentation of labor before confirmation of delay in labor.

---

### High-vs low-dose oxytocin protocols for labor induction: a systematic review and meta-analysis [^2f2d4db3]. American Journal of Obstetrics & Gynecology MFM (2025). Medium credibility.

Objective

This systematic review aimed to synthesize available literature reporting maternal and neonatal outcomes of induction of labor using high- vs low-dose oxytocin protocols.

Data Sources

PubMed, Embase, Scopus, CINAHL, and Cochrane databases, and ClinicalTrials.gov were searched from inception to January 17, 2023.

Study Eligibility Criteria

Studies with the following criteria were included: randomized or observational studies conducted with pregnant individuals, published in English, that compared low-dose (starting dose 0.5–2 milliunits/min increased by 1–2 milliunits/min every 15–40 minutes) vs high-dose (≥ 4 milliunits/min increased by 3–6 milliunits/min every 15–40 minutes) oxytocin infusion protocols for induction of labor. Studies of individuals with fetal death were excluded.

Study Appraisal and Synthesis Methods

Two reviewers independently extracted data and appraised study quality following the PRISMA guidelines and using the Cochrane risk of bias assessment tools. The primary outcome was cesarean delivery. Secondary outcomes included spontaneous vaginal delivery, operative vaginal delivery, duration of labor induction, uterine tachysystole, and maternal and neonatal morbidity outcomes. Pooled relative risks (RR) with 95% confidence intervals (CI) were calculated using random-effects models. Heterogeneity was assessed statistically using the Higgins' I 2 test and visually using a funnel plot.

Results

Six studies (two randomized controlled trials, four observational studies) were included, encompassing 7850 deliveries (3957 in the high-dose group and 3893 in the low-dose group). Overall, there was no difference in the risk of cesarean delivery following induction of labor with a high-dose oxytocin protocol compared with a low-dose protocol (26.0% vs 28.4%, pooled RR 1.02, 95% CI 0.85–1.21). There were also no differences in the likelihood of cesarean delivery for nonreassuring fetal status or neonatal morbidity, or in the duration of labor. Induction with high-dose oxytocin was associated with a lower frequency of postpartum hemorrhage, compared with a low-dose protocol (7.6% vs 9.9%, RR 0.78, 95% CI 0.66–0.92). Details of high- and low-dose protocols varied widely between studies, which all were at medium or high risk of bias. There was moderate heterogeneity (I 2 = 45.5%), and no evidence of publication bias (Harbord test, P = 0.74).

Conclusions

A synthesis of the existing literature demonstrates no difference in the frequency of cesarean delivery following induction of labor using a high- vs low-dose oxytocin protocol. However, this review highlights the methodological limitations of the few available published studies and the need for high-quality trials to guide optimal oxytocin dosing for labor induction.

---

### Labor augmentation strategies: what's the evidence? [^d21c338b]. Seminars in Perinatology (2020). Medium credibility.

Labor augmentation is a commonly used strategy in obstetrics to make labor more efficient or to increase the chance of achieving a vaginal delivery. Intravenous infusion of synthetic oxytocin and early amniotomy are the most widely used methods, but there is considerable variation in how they are used in clinical practice. There remain significant differences in the timing, dosing, and administration of synthetic oxytocin across institutions. The use and timing of amniotomy is similarly controversial. Much of the clinical variation in augmentation practices stem from the significant heterogeneity that exists in the literature, as well as the lack of an optimal strategy that has been subjected to the scientific scrutiny needed to prove its superiority in both efficacy and safety. Further research is needed to allow for better standardized care of women presenting in spontaneous labor.

---

### Oxytocin dosing during trial of labor after cesarean to minimize the risk of uterine rupture: a systematic review and meta-analysis [^65807c87]. American Journal of Obstetrics & Gynecology MFM (2025). Medium credibility.

Objective

Oxytocin remains the mainstay for induction and for the management of labor arrest during trial of labor after cesarean (TOLAC). Therefore, the clinical question should be not whether to use oxytocin, but how to optimize its administration. This meta-analysis aimed to assess which oxytocin protocol, in terms of initial dose, amount of increase, timing to next increase, and maximum dose, may minimize the risk of uterine rupture (UR) during TOLAC.

Data Sources

PubMed, Embase and Clinicaltrials.gov were searched up to September 21, 2024.

Study Eligibility Criteria

Randomized and nonrandomized studies evaluating the association between induction and/or augmentation with oxytocin and UR during TOLAC versus spontaneous TOLAC were eligible. To be included, studies had to report at least one parameter of the oxytocin protocol used (i.e., initial dose, amount of increase, timing to next increase, or maximum dose). The primary outcome was UR.

Methods

Effect measures were expressed as odds ratios (ORs) with 95% confidence intervals (CIs) and pooled using the Mantel-Haenszel method under a random-effects model. Oxytocin exposure was categorized to perform three separate meta-analyses, i.e., any use (for induction and/or augmentation), for induction only, and for augmentation only. In all three comparisons, subgroup analyses assessed differences based on oxytocin initial dose (≤ 2 vs > 2 mU/min), amount of increase (≤ 2 vs > 2 mU/min), timing to next increase (< 30 vs ≥ 30minutes), and maximum dose (≤ 20 vs > 20 mU/min).

Results

Twenty-one observational studies with 51,511 patients undergoing TOLAC were included. Oxytocin use during TOLAC was consistently associated with a significantly higher risk of UR across all analyses (any use: OR 1.94, 95% CI 1.36–2.77, p = 0.0003; induction only: OR 2.07, 95% CI, 1.28–3.36, p = 0.003; augmentation only: OR 2.03, 95% CI 1.22–3.38; p = 0.007). Among oxytocin protocol parameters, the initial oxytocin dose showed no relationship with UR risk. A significant association was found in some analyses only for increments ≤ 2 mU/min, though the > 2 mU/min subgroup was consistently underpowered. A higher risk of UR was uniformly observed when dose escalations were performed at intervals < 30 minutes. Both moderate (≤ 20 mU/min) and high (> 20 mU/min) maximum doses were significantly associated with increased odds, with a greater risk at higher doses.

Conclusions

These findings showed an association between oxytocin dosing during TOLAC and an increased risk of UR. Specifically, they suggest that both the timing and cumulative exposure of oxytocin, rather than the initial or incremental dose alone, may critically influence UR risk during TOLAC. Protocols adopting longer escalation intervals (≥ 30 minutes) and limiting maximum doses (≤ 20 mU/min) may enhance safety during TOLAC. Reliable evidence, such as that from randomized trials, is required to confirm these results and define the optimal oxytocin regimen in TOLAC management.

---

### Guideline no. 432c: induction of labour [^492d689a]. Journal of Obstetrics and Gynaecology Canada (2023). High credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, SOGC 2023 guidelines recommend to record oxytocin infusion rates in mU/min. Implement a local institutional protocol for oxytocin use with a safety checklist, regardless of infusion rate.

---

### Guideline no. 432c: induction of labour [^4b084b61]. Journal of Obstetrics and Gynaecology Canada (2023). High credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, SOGC 2023 guidelines recommend to administer oxytocin for labor induction when the modified Bishop score is ≥ 7, except in the setting of term pre-labor rupture of membranes.

---

### Discontinuation of intravenous oxytocin in the active phase of induced labour [^9eb940df]. The Cochrane Database of Systematic Reviews (2018). Low credibility.

Background

In most Western countries, obstetricians and midwives induce labour in about 25% of pregnant women. Oxytocin is an effective drug for this purpose, but associated with serious adverse effects of which uterine tachysystole, fetal distress and the need for immediate delivery are the most common. Various administration regimens such as reduced or pulsatile dosing have been suggested to minimise these. Discontinuation in the active phase of labour, i.e. when contractions are well-established and the cervix is dilated at least 5 cm is another method which may reduce adverse effects.

Objectives

To assess whether birth outcomes can be improved by discontinuation of intravenous (IV) oxytocin, initiated in the latent phase of induced labour, once active phase of labour is established.

Search Methods

We searched Cochrane Pregnancy and Childbirth's Trials Register (31 January 2018), Scopus, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP) (23 January 2018) together with reference checking, citation searching, and contact with study authors to identify additional studies.

Selection Criteria

Randomised controlled trials (RCTs) comparing discontinued IV with continuous IV oxytocin in the active phase of induced labour. No exclusion criteria were applied in terms of parity, maternal age, ethnicity, co-morbidity status, labour setting, gestational age, and prior caesarean delivery. Studies comparing different dosage regimens are outside the scope of this review.

Data Collection and Analysis

We used standard Cochrane methods.

Main Results

We found 10 completed RCTs involving 1888 women. One additional trial is ongoing. The included trials were conducted in hospital settings between February 1998 and January 2016, two in Europe (Denmark, and Greece), two in Turkey, and one each in Israel, Iran, USA, Bangladesh, India, and Thailand. Most trials included full-term singleton pregnancies with a fetus in vertex presentation. Some excluded women with cervical priming prior to induction and some excluded women with a history of prior caesarean delivery. When reported, the average age of the women ranged from 22 to 31 years, nulliparity from 45% to 68%, and pre-pregnancy body mass index from 22 to 32. Many of the included trials had design limitations and were judged to be at either high or unclear risk of bias across a number of 'Risk of bias' domains. Four trials included a Consort flow diagram. In three, this gave details of participants delivered before the active phase of labour, and treatment compliance for those who reached that stage. One Consort diagram only provided the latter information. The data in many of the trials without such a flow diagram were implausibly compliant with treatment allocation, suggesting that there had been silent post randomisation exclusions of women delivered before the active phase of labour. We therefore conducted a secondary analysis (not in our protocol) of caesarean section among women who reached the active phase of labour and were therefore eligible for the intervention. Our analysis by 'intention-to-treat' found that, compared with continuation of IV oxytocin stimulation, discontinuation of IV oxytocin may reduce the caesarean delivery rate, risk ratio (RR) 0.69, 95% confidence interval (CI) 0.56 to 0.86, 9 trials, 1784 women, low-level certainty. However, restricting our analysis to women who reached the active phase of labour (using 'reached active phase' as our denominator) suggests there is probably little or no difference between groups (RR 0.92, 95% CI 0.65 to 1.29, 4 trials, 787 women, moderate-certainty evidence). Discontinuation of IV oxytocin probably reduces the risk ofuterine tachysystole combined with abnormal fetal heart rate (FHR) compared with continued IV oxytocin (RR 0.15, 95% CI 0.05 to 0.46, 3 trials, 486 women, moderate-level certainty). We are uncertain about whether or not discontinuation increases the risk of chorioamnionitis (average RR 2.32, 95% CI 0.99 to 5.45, 1 trial, 252 women, very low-level certainty). Discontinuation of IV oxytocin may have little or no impact on the use of analgesia and epidural during labour compared to the use of continued IV oxytocin (RR 1.04 95% CI 0.95 to 1.14, 3 trials, 556 women, low-level certainty). Intrapartum cardiotocography (CTG) abnormalities (suspicious/pathological CTGs) are probably reduced by discontinuing IV oxytocin (RR 0.65, 95% CI 0.51 to 0.83, 7 trials, 1390 women, moderate-level certainty). Compared to continuing IV oxytocin, discontinuing IV oxytocin probably has little or no impact on the incidence of Apgar < 7 at five minutes (RR 0.78, 95% CI 0.27 to 2.21, 4 trials, 893 women, low-level certainty), or and acidotic cord gasses at birth (arterial umbilical pH < 7.10), (RR 1.03, 95% CI 0.50 to 2.13, 4 trials, 873 women, low-level certainty). Many of this review's maternal and infant secondary outcomes (including maternal and neonatal mortality) were not reported in the included trials.

Authors' Conclusions

Discontinuing IV oxytocin stimulation after the active phase of labour has been established may reduce caesarean delivery but the evidence for this was low certainty. When restricting our analysis to those trials that separately reported participants who reached the active phase of labour, our results showed there is probably little or no difference between groups. Discontinuing IV oxytocin may reduce uterine tachysystole combined with abnormal FHR. Most of the trials had 'Risk of bias' concerns which means that these results should be interpreted with caution. Our GRADE assessments ranged from very low certainty to moderate certainty. Downgrading decisions were based on study limitations, imprecision and indirectness. Future research could account for all women randomised and, in particular, note those who delivered before the point at which they would be eligible for the intervention (i.e. those who had caesareans in the latent phase), or because labour was so rapid that the infusion could not be stopped in time. Future trials could adopt the outcomes listed in this review including maternal and neonatal mortality, maternal satisfaction, and breastfeeding.

---

### Augmentation of labor: a review of oxytocin augmentation and active management of labor [^48a0e914]. Obstetrics and Gynecology Clinics of North America (2017). Low credibility.

Labor augmentation can be used to hasten labor, shorten the time to delivery, and perhaps reduce the risk of cesarean delivery. Particularly in women with longer labors or less frequent contractions, oxytocin augmentation seems to have positive impacts on these outcomes. Despite this, the evidence for augmentation alone on the risk of cesarean delivery is unclear, with varying evidence. More recently, oxytocin protocols have been recommended to standardize care and ensure patient safety.

---

### Labor induction techniques: which is the best? [^c2d29b3b]. Obstetrics and Gynecology Clinics of North America (2017). Low credibility.

Induction of labor is a common procedure undertaken whenever the benefits of prompt delivery outweigh the risks of expectant management. Cervical assessment is essential to determine the optimal approach. Indication for induction, clinical presentation and history, safety, cost, and patient preference may factor into the selection of methods. For the unfavorable cervix, several pharmacologic and mechanical methods are available, each with associated advantages and disadvantages. In women with a favorable cervix, combined use of amniotomy and intravenous oxytocin is generally the most effective approach. The goal of labor induction is to ensure the best possible outcome for mother and newborn.

---

### Guideline no. 432a: cervical ripening and induction of labour-general information [^e0ac425b]. Journal of Obstetrics and Gynaecology Canada (2023). High credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, SOGC 2023 guidelines recommend to consider administering either oral misoprostol or oxytocin for induction of labor in the setting of term pre-labor rupture of membranes, regardless of Bishop score.

---

### Continuous vs intermittent induction of labor with oxytocin in nulliparous patients: a randomized controlled trial [^8b537aa4]. American Journal of Obstetrics & Gynecology MFM (2023). Medium credibility.

Background

Oxytocin is considered the drug of choice for the induction of labor, although the optimal protocol and infusion duration remain to be determined.

Objective

This study aimed to assess whether the duration of oxytocin infusion increases 24-hour delivery rates and affects the length of time-to-delivery and patient's experience.

Study Design

A randomized controlled trial was performed at a single tertiary medical center, between January 1, 2020 and June 30, 2022. Nulliparous patients with a singleton pregnancy at a vertex presentation and a Bishop score ≥ 6 were randomly assigned to receive either continuous (16 hours, with a 4 hours pause in between infusions) or intermittent (8 hours, with a 4 hours pause in between infusions) oxytocin infusion, until delivery. In both groups, infusion was halted when signs of maternal or fetal compromise were observed. Randomization was conducted with a computer randomization sequence generation program. The primary outcome was delivery within 24 hours from the first oxytocin infusion and the secondary outcome included time-to-delivery, mode of delivery, and additional maternal and neonatal outcomes. Seventy-two patients per group were randomized to reach 80% statistical power with a 20% difference in the primary outcome according to previous studies.

Results

A total of 153 patients were randomized, 72 to the continuous oxytocin infusion group and 81 to the intermittent infusion group. The total oxytocin infusion time was similar between the groups. Patients in the continuous arm were more likely to deliver within 24 hours from oxytocin initiation (79.73% vs 62.96%, P < .05), and had a shorter oxytocin-to-delivery time interval, compared with patients receiving intermittent treatment (9.3 ± 3.7 hours vs 21 ± 11.7 hours, P < .001). Furthermore, time from ruptured membranes to delivery was shorter (9.3 ± 3.7 hours vs 21 ± 11.7 hours; P < .0001) and chorioamnionitis was less frequent (9.46% vs 21%; P < .05) in the continuous compared with the intermittent arm. Cesarean delivery rate was 20% in both groups (P = 0.226). There was no difference in postpartum hemorrhage, or adverse neonatal outcomes between the groups. Patients receiving continuous oxytocin infusion were more satisfied with the birthing experience.

Conclusion

Continuous infusion of oxytocin for labor induction in nulliparous patients with a favorable cervix may be superior to intermittent oxytocin infusion, because it shortens time-to-delivery, decreases chorioamnionitis rate, and improves maternal satisfaction, without affecting adverse maternal or neonatal outcomes.

---

### Discontinuing oxytocin infusion in the active phase of labor: a systematic review and meta-analysis [^5a2d2355]. Obstetrics and Gynecology (2017). Low credibility.

Objective

To evaluate the benefits and harms of discontinuation of oxytocin after the active phase of labor is reached.

Data Sources

Electronic databases (ie, MEDLINE, Scopus, ClinicalTrials.gov, EMBASE, ScienceDirect, the Cochrane Library at the CENTRAL Register of Controlled Trials, Scielo) were searched from their inception until April 2017.

Methods Of Study Selection

We included all randomized controlled trials comparing discontinuation (ie, intervention group) and continuation (ie, control group) of oxytocin infusion after the active phase of labor is reached, either after induction or augmentation of labor. Discontinuation of oxytocin infusion was defined as discontinuing oxytocin infusion when the active phase of labor was achieved. Continuation of oxytocin infusion was defined as continuing oxytocin infusion until delivery. Only trials in singleton gestations with vertex presentation at term were included. The primary outcome was the incidence of cesarean delivery.

Tabulation, Integration, and Results

Nine randomized controlled trials, including 1,538 singleton gestations, were identified as relevant and included in the meta-analysis. All nine trials included only women undergoing induction of labor. In the discontinuation group, if arrest of labor occurred, usually defined as no cervical dilation in 2 hours or inadequate uterine contractions for 2 hours or more, oxytocin infusion was restarted. Women in the control group had oxytocin continued until delivery usually at the same dose used at the time the active phase was reached. Women who were randomized to have discontinuation of oxytocin infusion after the active phase of labor was reached had a significantly lower risk of cesarean delivery (9.3% compared with 14.7%; relative risk 0.64, 95% CI 0.48–0.87) and of uterine tachysystole (6.2% compared with 13.1%; relative risk 0.53, 95% CI 0.33–0.84) compared with those who were randomized to have continuation of oxytocin infusion until delivery. Discontinuation of oxytocin infusion was associated with an increase in the duration of the active phase of labor (mean difference 27.65 minutes, 95% CI 3.94–51.36).

Conclusion

In singleton gestations with cephalic presentation at term undergoing induction, discontinuation of oxytocin infusion after the active phase of labor at approximately 5 cm is reached reduces the risk of cesarean delivery and of uterine tachysystole compared with continuous oxytocin infusion. Given this evidence, discontinuation of oxytocin infusion once the active stage of labor is established in women being induced should be considered as an alternative management plan.

---

### Oxytocin: physiology, pharmacology, and clinical application for labor management [^b7d8f87b]. American Journal of Obstetrics and Gynecology (2024). Medium credibility.

Oxytocin is a peptide hormone that plays a key role in regulating the female reproductive system, including during labor and lactation. It is produced primarily in the hypothalamus and secreted by the posterior pituitary gland. Oxytocin can also be administered as a medication to initiate or augment uterine contractions. To study the effectiveness and safety of oxytocin, previous studies have randomized patients to low- and high-dose oxytocin infusion protocols either alone or as part of an active management of labor strategy along with other interventions. These randomized trials demonstrated that active management of labor and high-dose oxytocin regimens can shorten the length of labor and reduce the incidence of clinical chorioamnionitis. The safety of high-dose oxytocin regimens is also supported by no associated differences in fetal heart rate abnormalities, postpartum hemorrhage, low Apgar scores, neonatal intensive care unit admissions, and umbilical artery acidemia. Most studies reported no differences in the cesarean delivery rates with active management of labor or high-dose oxytocin regimens, thereby further validating its safety. Oxytocin does not have a predictable dose response, thus the pharmacologic effects and the amplitude and frequency of uterine contractions are used as physiological parameters for oxytocin infusion titration to achieve adequate contractions at appropriate intervals. Used in error, oxytocin can cause patient harm, highlighting the importance of precise administration using infusion pumps, institutional safety checklists, and trained nursing staff to closely monitor uterine activity and fetal heart rate changes. In this review, we summarize the physiology, pharmacology, infusion regimens, and associated risks of oxytocin.

---

### WHO recommendations for augmentation of labour [^4ec3e1c3]. Geneva: World Health Organization (2014). Medium credibility.

Regarding preventative measures for induction of labor, more specifically with respect to prevention of delay, WHO 2014 guidelines recommend to do not use oxytocin to prevent delay in labor in patients receiving epidural analgesia.

---

### How to avoid iatrogenic morbidity and mortality while increasing availability of oxytocin and misoprostol for PPH prevention? [^3e3bdafc]. International Journal of Gynaecology and Obstetrics (2008). Low credibility.

Objective

Increased availability of oxytocin and misoprostol is needed to reduce the risk of postpartum hemorrhage. This review compiles rates and risks of adverse maternal and perinatal outcomes associated with use of these medications for labor induction and augmentation in low-income countries. Recommendations are proposed based on the findings.

Methods

We did a structured literature review using 5 databases followed by analysis of induction and augmentation rates from existing data.

Results

Combined induction and augmentation rates were documented in up to 50% of hospital-based deliveries identified in the databases. Data are sparse but suggest associations between induction/augmentation and stillbirth, neonatal resuscitation, and uterine rupture, and inappropriate administration of oxytocin and misoprostol both outside and inside healthcare systems in low-income countries.

Conclusions

Guidelines for labor induction/augmentation are needed specifically for low resourced settings. Rigorous studies should be pursued to quantify the magnitude and effect of inappropriate induction and augmentation on maternal and perinatal morbidity and mortality. Programs are needed to ensure community-wide awareness of the adverse effects of the improper use of these drugs on mothers and babies, especially in out-of-hospital settings.

---

### Maternal plasma levels of oxytocin during physiological childbirth-a systematic review with implications for uterine contractions and central actions of oxytocin [^8ffc8a45]. BMC Pregnancy and Childbirth (2019). Medium credibility.

Implications for clinical use of synthetic oxytocin in labour and birth

Following on from the findings of our systematic review, an important question is: "How can the administration of synthetic oxytocin in labour and birth imitate physiological patterns and effects, as far as possible?"

From this perspective, a more physiological method of administering synthetic oxytocin would be to use a pulsatile infusion pattern, which is more aligned with labour physiology. Several studies have found that the total dose requirement of oxytocin is 20 to 60% reduced with pulsatile administration compared to continuous infusions. In addition, there is generally less hyperstimulation, and equivalent outcomes for mothers and babies such as caesarean rates and outcomes for the baby. In addition, a recent in vitro study has suggested that the pulsatile administration pattern of oxytocin may maintain myometrial receptor sensitivity and therfore maintain uterine contractility.

Another possible conclusion from the recent pharmacokinetic data, which show a relatively longer half-life of oxytocin than currently assumed, would be that doses should not be increased with too short intervals. Intervals of 30–40 min rather than 15 min would be consistent with these understandings. Too-short dosing intervals could lead to unnecessarily high cumulative exposures, as levels are increased before the full effects of the previous doses are achieved. In order to achieve the lowest dose exposure, it makes sense to carefully titrate the dose against effect, taking into account this pharmacokinetic data. Arithmetical vs geometric dose increases would be more consistent with low dose exposure.

These hypotheses and models need to be thoroughly studied in relation to the use of synthetic oxytocin in labour, especially given its widespread use.

---

### High-dose versus low-dose oxytocin for augmentation of delayed labour [^b267d80c]. The Cochrane Database of Systematic Reviews (2013). Low credibility.

Background

A major cause of failure to achieve spontaneous vaginal birth is delay in labour due to presumed inefficient uterine action. Oxytocin is given to increase contractions and high-dose regimens may potentially increase the number of spontaneous vaginal births, but as oxytocin can cause hyperstimulation of the uterus, there is a possibility of increased adverse events.

Objectives

To compare starting dose and increment dose of oxytocin for augmentation for women delayed in labour to determine whether augmentation by high-dose regimens of oxytocin improves labour outcomes and to examine the effect on both maternal/neonatal outcomes and women's birth experiences.

Search Methods

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 May 2013) and reference lists of retrieved studies.

Selection Criteria

We included all randomised and quasi-randomised controlled trials for women in delayed labour requiring augmentation by oxytocin comparing high-dose regimens (defined as starting dose and increment of equal to or more than 4 mU per minute) with low-dose regimens (defined as starting dose and an increment of less than 4 mU per minute). Increase interval: between 15 and 40 minutes. The separation of low- and high-dose regimens is based on an arbitrary decision.

Data Collection and Analysis

Four review authors undertook assessment of trial eligibility, risk of bias, and data extraction independently.

Main Results

We included four studies involving 644 pregnant women. Three studies were randomised controlled trials and one trial was a quasi-randomised study. A higher dose of oxytocin was associated with a significant reduction in length of labour reported from one trial (mean difference (MD) -3.50 hours; 95% confidence interval (CI) -6.38 to -0.62; one trial, 40 women). There was a decrease in the rate of caesarean section (risk ratio (RR) 0.62; 95% CI 0.44 to 0.86 four trials, 644 women) and an increase in the rate of spontaneous vaginal birth in the high-dose group (RR 1.35; 95% CI 1.13 to 1.62, three trials, 444 women), although for both of these outcomes there were inconsistencies between studies in the size of effect. When we carried out sensitivity analysis (temporarily removing a study at high risk of bias) the differences between groups were no longer statistically significantThere were no significant differences between high- and low-dose regimens for instrumental vaginal birth, epidural analgesia, hyperstimulation, postpartum haemorrhage, chorioamnionitis or women's perceptions of experiences. For neonatal outcomes, there was no significant difference between groups for Apgar scores, umbilical cord pH, admission to special care baby unit, or neonatal mortality. The following outcomes were not evaluated in the included studies: perinatal mortality, uterine rupture, abnormal cardiotocography, women's pyrexia, dystocia and neonatal neurological morbidity.

Authors' Conclusions

Higher-dose regimens of oxytocin (4 mU per minute or more) were associated with a reduction in the length of labour and in caesarean section, and an increase in spontaneous vaginal birth. However, there is insufficient evidence to recommend that high-dose regimens are advised routinely for women with delay in the first stage of labour. Further research should evaluate the effect of high-dose regimens of oxytocin for women delayed in labour and should include maternal and neonatal outcomes as well as the effects on women.

---

### The physiology and pharmacology of oxytocin in labor and in the peripartum period [^b2aa42cb]. American Journal of Obstetrics and Gynecology (2024). Medium credibility.

Oxytocin is a reproductive hormone implicated in the process of parturition and widely used during labor. Oxytocin is produced within the supraoptic nucleus and paraventricular nucleus of the hypothalamus and released from the posterior pituitary lobe into the circulation. Oxytocin is released in pulses with increasing frequency and amplitude in the first and second stages of labor, with a few pulses released in the third stage of labor. During labor, the fetus exerts pressure on the cervix of the uterus, which activates a feedforward reflex-the Ferguson reflex-which releases oxytocin. When myometrial contractions activate sympathetic nerves, it decreases oxytocin release. When oxytocin binds to specific myometrial oxytocin receptors, it induces myometrial contractions. High levels of circulating estrogen at term make the receptors more sensitive. In addition, oxytocin stimulates prostaglandin synthesis and release in the decidua and chorioamniotic membranes by activating a specific type of oxytocin receptor. Prostaglandins contribute to cervical ripening and uterine contractility in labor. The oxytocin system in the brain has been implicated in decreasing maternal levels of fear, pain, and stress, and oxytocin release and function during labor are stimulated by a social support. Moreover, studies suggest, but have not yet proven, that labor may be associated with long-term, behavioral and physiological adaptations in the mother and infant, possibly involving epigenetic modulation of oxytocin production and release and the oxytocin receptor. In addition, infusions of synthetic oxytocin are used to induce and augment labor. Oxytocin may be administered according to different dose regimens at increasing rates from 1 to 3 mIU/min to a maximal rate of 36 mIU/min at 15- to 40-minute intervals. The total amount of synthetic oxytocin given during labor can be 5 to 10 IU, but lower and higher amounts of oxytocin may also be given. High-dose infusions of oxytocin may shorten the duration of labor by up to 2 hours compared with no infusion of oxytocin; however, it does not lower the frequency of cesarean delivery. When synthetic oxytocin is administered, the plasma concentration of oxytocin increases in a dose-dependent way: at infusion rates of 20 to 30 mIU/min, plasma oxytocin concentration increases approximately 2- to 3-fold above the basal level. Synthetic oxytocin administered at recommended dose levels is not likely to cross the placenta or maternal blood-brain barrier. Synthetic oxytocin should be administered with caution as high levels may induce tachystole and uterine overstimulation, with potentially negative consequences for the fetus and possibly the mother. Of note, 5 to 10 IU of synthetic oxytocin is often routinely given as an intravenous or intramuscular bolus administration after delivery to induce uterine contractility, which, in turn, induces uterine separation of the placenta and prevents postpartum hemorrhage. Furthermore, it promotes the expulsion of the placenta.

---

### First and second stage labor management: ACOG clinical practice guideline no. 8 [^dbeb7bfb]. Obstetrics and Gynecology (2024). High credibility.

Oxytocin dosing strategies — ACOG recommends either low-dose or high-dose oxytocin strategies as reasonable approaches to the active management of labor to reduce operative deliveries (STRONG RECOMMENDATION, HIGH-QUALITY EVIDENCE).

---

### Management of spontaneous labour at term in healthy women [^2bb46ba4]. Journal of Obstetrics and Gynaecology Canada (2016). Medium credibility.

Regarding medical management for labor dystocia, more specifically with respect to oxytocin, SOGC 2016 guidelines recommend to recognize that high-dose oxytocin regimens have been shown to decrease labor duration compared with low-dose regimens. Administer the lowest dose needed to produce normal progress to reduce the risk of tachysystole or excessive uterine activity and to create a uterine contraction pattern of 3–5 contractions or ≥ 200 Montevideo units every 10 minutes.

---

### Care of late intrauterine fetal death and stillbirth: green-top guideline no. 55 [^4c1e08aa]. BJOG (2025). High credibility.

Regarding therapeutic procedures for stillbirth, more specifically with respect to induction of labor, RCOG 2025 guidelines recommend to consider administering oxytocin augmentation for vaginal delivery after a previous C-section, but make the decision following a discussion with a consultant or obstetrician with equivalent training.

---

### Oxytocin: new perspectives on an old drug [^5af68d64]. American Journal of Obstetrics and Gynecology (2009). Low credibility.

Oxytocin is the drug most commonly associated with preventable adverse perinatal outcomes and was recently added by the Institute for Safe Medication Practices to a small list of medications "bearing a heightened risk of harm", which may "require special safeguards to reduce the risk of error". Current recommendations for the administration of this drug are vague with respect to indications, timing, dosage, and monitoring of maternal and fetal effects. A review of available clinical and pharmacologic data suggests that specific, evidence-based guidelines for the intrapartum administration of oxytocin may be derived from available data. If implemented, such practices may reduce the likelihood of patient harm. These suggested guidelines focus on limited elective administration of oxytocin, consideration of strategies that have been shown to decrease the need for indicated oxytocin use, reliance on low-dose oxytocin regimens, adherence to specific semiquantitative definitions of adequate and inadequate labor, and an acceptance that once adequate uterine activity has been achieved, more time rather than more oxytocin is generally preferable. The use of conservative, specific protocols for monitoring the effects of oxytocin on mother and fetus is likely not only to improve outcomes but also reduce conflict between members of the obstetric team. Implementation of these guidelines would seem appropriate in a culture increasingly focused on patient safety.

---

### Guideline no. 432c: induction of labour [^f5f3b590]. Journal of Obstetrics and Gynaecology Canada (2023). High credibility.

Regarding medical management for induction of labor, more specifically with respect to oxytocin, SOGC 2023 guidelines recommend to initiate oxytocin no earlier than 30 minutes after prostaglandin E2 vaginal insert removal, 6 hours after prostaglandin E2 vaginal gel insertion, 2 hours after oral prostaglandin E1, and 4 hours after vaginal prostaglandin E1 insertion.

---

### Guideline no. 432a: cervical ripening and induction of labour-general information [^d95f3c43]. Journal of Obstetrics and Gynaecology Canada (2023). High credibility.

Regarding medical management for induction of labor, more specifically with respect to prostaglandins, SOGC 2023 guidelines recommend to consider administering either oral misoprostol or oxytocin for induction of labor in the setting of term pre-labor rupture of membranes, regardless of Bishop score.

---

### Improving patient safety and uniformity of care by a standardized regimen for the use of oxytocin [^10af3398]. American Journal of Obstetrics and Gynecology (2008). Low credibility.

Oxytocin is 1 of the most commonly used drugs in labor and has been associated with adverse maternal and fetal outcomes. In an attempt to improve patient safety, we constructed a standardized protocol for labor induction with oxytocin. We reviewed the numerous publications regarding oxytocin use for either induction or augmentation of labor in order to determine if there was a protocol available that would maximize success of delivery and minimize the adverse maternal and fetal effects of the drug. Using the literature review and the specific pharmacokinetics of oxytocin, we developed a standardized approach for the dilution and administration of oxytocin in order to improve patient safety, develop uniformity of the drug use, maximize its benefits, and minimize its side effects. We suggest that a standardized approach to oxytocin use be adopted that uses an oxytocin dilution of 10 mU/mL, initial dose of 2 mU/min (12 mL/hr), incremental increase of 2 mU (12 mL) every 45 minutes until adequate labor with the maximum dose being 16 mU/min (96 mL/hr).

---

### First and second stage labor management: ACOG clinical practice guideline no. 8 [^9981904e]. Obstetrics and Gynecology (2024). High credibility.

Regarding medical management for labor dystocia, more specifically with respect to oxytocin, ACOG 2024 guidelines recommend to administer either low-dose or high-dose oxytocin for the active management of labor to reduce operative deliveries.

---

### Oxytocin administration for induction and augmentation of labour in Polish maternity units-an observational study [^aa1901f9]. BMC Pregnancy and Childbirth (2021). Medium credibility.

Background

The number of women who have their labour induced or augmented with synthetic oxytocin is increasing in high-income countries throughout the world. At the same time, there are considerable differences in the intrapartum oxytocin administration regimens between and within countries, regions and hospitals in Europe. In Poland, there is no official data regarding oxytocin administration. Surveys addressed to women who had given birth revealed that between 43 and 63% of all births are induced or stimulated with synthetic oxytocin. In 2017, the Polish Society of Gynaecologists and Obstetricians (PSOGO) issued national guidelines on the use of synthetic oxytocin for labour induction and augmentation. They recommend two oxytocin administration regimens: (i) low dose (start dose 0.5–2 milliUnits per minute (mU/min), escalating at 1–2 mU/min at 15–40 min intervals) and (ii) high dose (start dose 6 mU/min, escalating at 3–6 mU/min at 15–40 min intervals). The guidelines also state that there are no apparent benefits to continuing oxytocin infusion after achieving effective uterine contractions and reaching the active phase of labour (dilatation > 5 cm). The guidelines on the use of synthetic oxytocin for labour induction and augmentation do not include case-specific variations (obese women, multiple pregnancies etc).

However, there is not enough data regarding practices and protocols that healthcare personnel follow and the dose of oxytocin that women receive during labour. Observed differences in the practice of oxytocin use should stimulate efforts to standardise the procedures. Following a strict protocol may face resistance from those responsible for labour care.

Routine oxytocin use presents no benefits when there are no medical indications for labour augmentation. Despite its widespread use during labour, and its effectiveness in labour induction and augmentation, there is still little research on the short and long-term consequences of synthetic oxytocin on both the woman and child.

While an increasing number of studies suggest possible adverse effects of intrapartum synthetic oxytocin, there is little research on the impact on the mother and the baby of the total and cumulative dose of synthetic oxytocin administered during labour. These studies concentrate primarily on the effects of maternal obesity and indicate that significantly higher dosages of oxytocin are used in obese women. Additionally, the Carlson study shows that hourly oxytocin dose in obese women was also related to neonatal birth weight and cervical dilation at oxytocin initiation.

---

### How effective are the components of active management of the third stage of labor? [^a0594f63]. BMC Pregnancy and Childbirth (2013). Low credibility.

Conclusions

Our findings call into question current consensus regarding the provision of AMTSL components and suggest that practice guidelines should account for setting-related differences such as the availability of oxytocin and its route of administration. The optimal combination of interventions will vary accordingly.

---

### High dose versus low dose oxytocin for augmentation of delayed labour [^c75fd467]. The Cochrane Database of Systematic Reviews (2011). Low credibility.

Background

A major cause of failure to achieve spontaneous vaginal birth is delay in labour caused by presumed inefficient uterine action. High dose may potentially increase the number of spontaneous vaginal births, but as oxytocin can cause hyperstimulation of the uterus, there is a possibility of increased adverse events.

Objectives

To compare starting dose and increment of amount of oxytocin for augmentation for women delayed in labour to determine whether augmentation by high dose of oxytocin improves labour outcomes and the effect on both maternal/neonatal outcomes and women's birth experiences.

Search Strategy

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (28 February 2011) and reference lists of retrieved studies.

Selection Criteria

We included all randomised and quasi-randomised controlled trials for women in delayed in labour requiring augmentation by oxytocin comparing high starting and increment dose (defined as starting dose and increment of equal to or more than 4 mU per minute) with low dose (defined as starting dose and an increment of less than 4 mU per minute. Increase interval: between 15 and 40 minutes. The separation of low and high doses is based on an arbitrary decision.

Data Collection and Analysis

Three review authors undertook assessment of trial eligibility, risk of bias, and data extraction independently.

Main Results

We included four studies involving 660 pregnant women. Three studies were randomised controlled trials and one trial was a quasi-randomised study. A higher dose of oxytocin was associated with a significant reduction in length of labour reported from one trial (mean difference (MD) -3.50 hours; 95% confidence interval (CI) -6.38 to -0.62; one trial, 40 women). There was a decrease in rate of caesarean section (risk ratio (RR) 0.53; 95% CI 0.38 to 0.75, four trials, 650 women) and an increase in the rate of spontaneous vaginal birth (RR 1.37; 95% CI 1.15 to 1.64, two trials, 350 women). There were no significant differences for neonatal mortality, hyperstimulation, chorioamnionitis, epidural analgesia; or neonatal outcomes of Apgar scores, umbilical cord pH or admission to special care baby unit. The following outcomes were not evaluated in the included studies: perinatal mortality, women's satisfaction, instrumental vaginal birth, uterine rupture, postpartum haemorrhage, abnormal cardiotocography, women's pyrexia, dystocia and neonatal neurological morbidity.

Authors' Conclusions

Higher dose of oxytocin starting and increment dose (4 mU per minute or more) was associated with a reduction in the length of labour and in caesarean section, and an increase in spontaneous vaginal birth. However, there is insufficient evidence. The number of studies and the quality of the available evidence is of concern. Additionally, there is insufficient evidence for other maternal and neonatal outcomes, and how women feel about the higher doses of oxytocin. Therefore, no firm recommendation can be made. Further research should evaluate the effect of high dose oxytocin for women delayed in labour and should include these outcomes.

---

### CONDISOX-continued versus discontinued oxytocin stimulation of induced labour in a double-blind randomised controlled trial [^b4ab848d]. BMC Pregnancy and Childbirth (2019). Medium credibility.

Background

Oxytocin is an effective drug for induction of labour, but is associated with serious adverse effects of which uterine tachysystole, fetal distress and the need of immediate delivery are the most common. Discontinuation of oxytocin once the active phase of labour is established could reduce the adverse effects. The objective is to investigate how the caesarean section rate is affected when oxytocin stimulation is discontinued in the active phase of labour compared to labours where oxytocin is continued.

Methods

CONDISOX is a double-blind multicentre randomised controlled trial conducted at Danish and Dutch Departments of Obstetrics and Gynaecology. The first participant was recruited on April 8 2016. Based on a clinically relevant relative reduction in caesarean section rate of 7%, an alpha of 0.05, a beta of 80%, we aim for 1200 participating women (600 in each arm). The CONDISOX trial includes women at a gestational age of 37–42 complete weeks of pregnancy, who have uterine activity stimulated with oxytocin infusion for the induction of labour. Women are randomised when the active phase of labour becomes established, to study medication containing either oxytocin (continuous group) or placebo (discontinued group) infusion. Women are stratified by birth site, indication for oxytocin stimulation (induction of labour, prelabour rupture of membranes) and parity (nulliparous, parous ± previous caesarean section). We will compare the primary outcome, caesarean section rate, in the two groups using a chi-square test with a p-value of 0.05. If superiority is not demonstrated, we have a pre-defined post hoc non-inferiority boundary (margin, delta) at 1.09. Secondary outcomes include duration of the active phase of labour, incidence of uterine tachysystole, postpartum haemorrhage, admission to the neonatal intensive care unit, Apgar score, umbilical arterial blood pH, and birth experience.

Discussion

The high frequency of oxytocin use and the potential risks of both maternal and fetal adverse effects of oxytocin emphasise the need to determine the optimal oxytocin regime for induction of labour.

Trial Registration

NCT02553226 (registered September 17, 2015). Eudra-CT number: 2015-002942-30.

---

### CDC clinical practice guideline for prescribing opioids… [^af48c402]. CDC (2025). Medium credibility.

This guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥ 18 years. It updates the CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 and includes recommendations for managing acute, subacute, and chronic pain. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative or end-of-life care. The guideline addresses the following four areas: 1) determining whether or not to initiate opioids for pain, 2) selecting opioids and determining opioid dosages, 3) deciding duration of initial opioid prescription and conducting follow-up, and 4) assessing risk and addressing potential harms of opioid use.

CDC recommends that persons with pain receive appropriate pain treatment, with careful consideration of the benefits and risks of all treatment options in the context of the patient's circumstances. Recommendations should not be applied as inflexible standards of care across patient populations. This clinical practice guideline is intended to improve communication between clinicians and patients about the benefits and risks of pain treatments, including opioid therapy; improve the effectiveness and safety of pain treatment; mitigate pain; improve function and quality of life for patients with pain; and reduce risks associated with opioid pain therapy, including opioid use disorder, overdose, and death.

Scope and Audience This clinical practice guideline is intended for clinicians who are treating outpatients aged ≥ 18 years with acute, subacute, or chronic pain, and excludes pain management related to sickle cell disease, cancer-related pain treatment, palliative care, and end-of-life care. The AHRQ review of opioids for chronic pain updated and expanded the evidence for the 2016 CDC review; studies were included on short-term, intermediate-term and long-term outcomes of therapy involving opioids, effects of opioid plus nonopioid combination therapy, effects of tramadol, effects of naloxone coprescription, risks of coprescribed benzodiazepines, risks of coprescribed gabapentinoids, and effects of concurrent use of cannabis.

---

### Management of spontaneous labour at term in healthy women [^93ef4ae5]. Journal of Obstetrics and Gynaecology Canada (2016). Medium credibility.

Regarding medical management for labor dystocia, more specifically with respect to oxytocin, SOGC 2016 guidelines recommend to consider administering oxytocin, in addition to other measures, once a diagnosis of dystocia has been made in either the first or second stage of labor.

---

### Continuation versus discontinuation of intravenous oxytocin in the active phase of labour [^7284f2c0]. The Cochrane Database of Systematic Reviews (2024). Medium credibility.

Objectives

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of discontinuing intravenous oxytocin stimulation in pregnant women during the active phase of induced or augmented labour.

---

### Guideline no. 432c: induction of labour [^5afbacfd]. Journal of Obstetrics and Gynaecology Canada (2023). High credibility.

Regarding medical management for induction of labor, more specifically with respect to prostaglandins, SOGC 2023 guidelines recommend to administer oral prostaglandin E1 or IV oxytocin with amniotomy as the preferred method of induction of labor when the Bishop score is ≥ 7.

---

### Guideline no. 432b: cervical ripening [^e4d8f626]. Journal of Obstetrics and Gynaecology Canada (2023). High credibility.

Regarding medical management for induction of labor, more specifically with respect to cervical ripening, SOGC 2023 guidelines recommend to do not routinely offer amniotomy or oxytocin, individually or in combination, until the modified Bishop score is ≥ 7.

---

### Oxytocin administration for induction and augmentation of labour in Polish maternity units-an observational study [^5b3befd8]. BMC Pregnancy and Childbirth (2021). Medium credibility.

Studying these aspects is particularly crucial in the light of the latest reports on the longer than the previously believed half-life of oxytocin that can lead to high accumulation and unnecessary exposure in women.

This study aimed to assess administration practices of oxytocin for labour induction and augmentation in two maternity units in Poland. First, the assessment included calculation of the total amount of oxytocin provided from the beginning of labour until delivery (including the III and IV stage of labour) and cumulative dose of oxytocin administered to women during labour (the amount of oxytocin given until the birth of the neonate). Then, the relationship between the cumulative dose of oxytocin and short term perinatal outcomes (mode of delivery, use of epidural anaesthesia, Apgar scores, birth weight and postpartum blood loss) was analysed. Finally, compliance of administration practices with national guidelines was analysed.

---

### Patterns of oxytocin use for induction and augmentation of labour among healthcare providers in Nigeria [^ecd09e55]. BMC Pregnancy and Childbirth (2024). Medium credibility.

Introduction

In recent times, evidence shows that more women undergo intrapartum use of oxytocin for induction and augmentation of labour, to deliver babies in the quest to shorten the duration of labour. The World Health Organization recommends oxytocin, a uterotonic as a pharmacologic option for induction and augmentation of labour. Induction of labour is one of the most common obstetric procedures and is performed in approximately 25% of all pregnancies in both high-income and low-middle-income countries. It is indicated when the risks of continuing the pregnancy outweigh the risks of induction, with the goal of delivery while minimizing risks to the mother and newborn. Induction is usually performed by administering intravenous (IV) oxytocin or prostaglandins or the manual rupturing of amniotic membrane to prevent the adverse outcomes associated with prolonged pregnancy. Augmentation of labour is used to accelerate labour, shorten the time to delivery, and perhaps reduce the risk of caesarean delivery, particularly in women with longer labour or less frequent contractions. It involves the stimulation of the uterus to increase the frequency, duration and intensity of contractions after the onset of labour to prevent delay in the first stage of labour. Generally, labour augmentation has been done with intravenous infusion infusion of oxytocin and/or amniotomy.

Oxytocin when used for labour induction/augmentation can cause both maternal and foetal adverse outcomes, hence the need for strict adherence to recommendations and adequate provision for close monitoring. Oxytocin used during labour has been associated with increased risks of neonatal encephalopathy, and increases the volume of blood loss during vaginal birth. A Cochrane systematic review has shown that oxytocin used during labour has poor efficacy in reducing rates of caesarean section, and instrumental deliveries and is associated with uterine hyperstimulation and foetal heart rate changes.

In spontaneous labour, endogenous oxytocin release has been observed to follow a pulsatile pattern, with increasing pulse frequency, and short-lasting peaks start to occur at term to a maximum of three pulses/10 minutes. However, synthetic oxytocin that is infused follows a flat pattern of release causing a different pattern of uterine contractions from that of physiological labour leading to irregular, more frequent, longer, and more painful contractions. With oxytocin infusion at a dose of 0.6 International units/hour (IU/hour), the plasma level falls within the range of oxytocin level in physiological birth, but infusions influence the plasma levels in a dose-dependent pattern and doubling the dose results in doubling of the oxytocin levels and associated side effects unlike in physiological labour.

---

### First and second stage labor management: ACOG clinical practice guideline no. 8 [^dd0681eb]. Obstetrics and Gynecology (2024). High credibility.

ACOG — Management of dystocia in the first stage of labor — ACOG recommends amniotomy for patients undergoing augmentation or induction of labor to reduce the duration of labor (STRONG RECOMMENDATION, HIGH-QUALITY EVIDENCE); ACOG recommends either low-dose or high-dose oxytocin strategies as reasonable approaches to the active management of labor to reduce operative deliveries (STRONG RECOMMENDATION, HIGH-QUALITY EVIDENCE); and ACOG recommends using intrauterine pressure catheters among patients with ruptured membranes to determine adequacy of uterine contractions in those with protracted active labor or when contractions cannot be accurately externally monitored (STRONG RECOMMENDATION, LOWQUALITY EVIDENCE).

---

### Maternal and newborn plasma oxytocin levels in response to maternal synthetic oxytocin administration during labour, birth and postpartum-a systematic review with implications for the function of the oxytocinergic system [^af712e09]. BMC Pregnancy and Childbirth (2023). Medium credibility.

Background

The reproductive hormone oxytocin facilitates labour, birth and postpartum adaptations for women and newborns. Synthetic oxytocin is commonly given to induce or augment labour and to decrease postpartum bleeding.

Aim

To systematically review studies measuring plasma oxytocin levels in women and newborns following maternal administration of synthetic oxytocin during labour, birth and/or postpartum and to consider possible impacts on endogenous oxytocin and related systems.

Methods

Systematic searches of PubMed, CINAHL, PsycInfo and Scopus databases followed PRISMA guidelines, including all peer-reviewed studies in languages understood by the authors. Thirty-five publications met inclusion criteria, including 1373 women and 148 newborns. Studies varied substantially in design and methodology, so classical meta-analysis was not possible. Therefore, results were categorized, analysed and summarised in text and tables.

Results

Infusions of synthetic oxytocin increased maternal plasma oxytocin levels dose-dependently; doubling the infusion rate approximately doubled oxytocin levels. Infusions below 10 milliunits per minute (mU/min) did not raise maternal oxytocin above the range observed in physiological labour. At high intrapartum infusion rates (up to 32 mU/min) maternal plasma oxytocin reached 2–3 times physiological levels.

Postpartum synthetic oxytocin regimens used comparatively higher doses with shorter duration compared to labour, giving greater but transient maternal oxytocin elevations. Total postpartum dose was comparable to total intrapartum dose following vaginal birth, but post-caesarean dosages were higher.

Newborn oxytocin levels were higher in the umbilical artery vs. umbilical vein, and both were higher than maternal plasma levels, implying substantial fetal oxytocin production in labour. Newborn oxytocin levels were not further elevated following maternal intrapartum synthetic oxytocin, suggesting that synthetic oxytocin at clinical doses does not cross from mother to fetus.

Conclusions

Synthetic oxytocin infusion during labour increased maternal plasma oxytocin levels 2–3-fold at the highest doses and was not associated with neonatal plasma oxytocin elevations. Therefore, direct effects from synthetic oxytocin transfer to maternal brain or fetus are unlikely. However, infusions of synthetic oxytocin in labour change uterine contraction patterns. This may influence uterine blood flow and maternal autonomic nervous system activity, potentially harming the fetus and increasing maternal pain and stress.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12884-022-05221-w.

---

### Labor dystocia in nulliparous women [^cfad1e37]. American Family Physician (2021). High credibility.

Regarding medical management for labor dystocia, more specifically with respect to oxytocin, AAFP 2021 guidelines recommend to administer low-dose over high-dose oxytocin regimens for labor augmentation.

---

### Intravenous oxytocin alone for cervical ripening and induction of labour [^de68e02e]. The Cochrane Database of Systematic Reviews (2001). Low credibility.

Background

Oxytocin is the commonest induction agent used worldwide. It has been used alone, in combination with amniotomy or following cervical ripening with other pharmacological or non-pharmacological methods. Prior to the introduction of prostaglandin agents oxytocin was used as a cervical ripening agent as well. In developed countries oxytocin alone is more commonly used in the presence of ruptured membranes whether spontaneous or artificial. In developing countries where the incidence of HIV is high, delaying amniotomy in labour reduces vertical transmission rates and hence the use of oxytocin with intact membranes warrants further investigation. This review will address the use of oxytocin alone for induction of labour. Amniotomy alone or oxytocin with amniotomy for induction of labour has been reviewed elsewhere in the Cochrane Library. Trials which consider concomitant administration of oxytocin and amniotomy will not be considered. This is one of a series of reviews of methods of cervical ripening and labour induction using a standardised methodology.

Objectives

To determine the effects of oxytocin alone for third trimester cervical ripening or induction of labour in comparison with other methods of induction of labour or placebo/no treatment.

Search Strategy

The Cochrane Pregnancy and Childbirth Group Trials Register, the Cochrane Controlled Trials Register and bibliographies of relevant papers. Last searched: May 2001.

Selection Criteria

The criteria for inclusion included the following: (1) clinical trials comparing vaginal prostaglandins used for third trimester cervical ripening or labour induction with placebo/no treatment or other methods listed above it on a predefined list of labour induction methods; (2) random allocation to the treatment or control group; (3) adequate allocation concealment; (4) violations of allocated management not sufficient to materially affect conclusions; (5) clinically meaningful outcome measures reported; (6) data available for analysis according to the random allocation; (7) missing data insufficient to materially affect the conclusions.

Data Collection and Analysis

A strategy was developed to deal with the large volume and complexity of trial data relating to labour induction. This involved a two-stage method of data extraction. The initial data extraction was done centrally, and incorporated into a series of primary reviews arranged by methods of induction of labour, following a standardised methodology. The data is to be extracted from the primary reviews into a series of secondary reviews, arranged by category of woman.

Main Results

In total, 110 trials were considered; 52 have been excluded and 58 included examining a total of 11,129 women. Comparing oxytocin alone with expectant management: Oxytocin alone reduced the rate of unsuccessful vaginal delivery within 24 hours when compared with expectant management (8.3% versus 54%, relative risk (RR) 0.16, 95% confidence interval (CI) 0.10,0.25) but the caesarean section rate was increased (10.4% versus 8.9%, RR 1.17, 95% CI 1.01,1.36). This increase in caesarean section rate was not apparent in the subgroup analyses. Women were less likely to be unsatisfied with induction rather than expectant management, in the one trial reporting this outcome (5.5% versus 13.7%, RR 0.43, 95% CI 0.33, 0.56). Comparing oxytocin alone with vaginal prostaglandins: Oxytocin alone was associated with an increase in unsuccessful vaginal delivery within 24 hours (52% versus 28%, RR 1.85, 95% CI 1.41, 2.43), irrespective of membrane status, but there was no difference in caesarean section rates (11.4% versus 10%, RR 1.12, 95% CI 0.95, 1.33). Comparing oxytocin alone with intracervical prostaglandins: Oxytocin alone was associated with an increase in unsuccessful vaginal delivery within 24 hours when compared with intracervical PGE2 (51% versus 35%, RR 1.49, 95% CI 1.12,1.99). For all women with an unfavourable cervix regardless of membrane status, the caesarean section rates were increased (19.0% versus 13.1%, RR 1.42, 95% CI 1.11, 1.82).

Reviewer's Conclusions

Overall, comparison of oxytocin alone with either intravaginal or intracervical PGE2 reveals that the prostaglandin agents probably overall have more benefits than oxytocin alone. The amount of information relating to specific clinical subgroups is limited, especially with respect to women with intact membranes. Comparison of oxytocin alone to vaginal PGE2 in women with ruptured membranes reveals that both interventions are probably equally efficacious with each having some advantages and disadvantages over the others. With respect to current practice in women with ruptured membranes induction can be recommended by either method and in women with intact membranes there is insufficient information to make firm recommendations.

---

### Oxytocin administration for induction and augmentation of labour in Polish maternity units-an observational study [^35d890f8]. BMC Pregnancy and Childbirth (2021). Medium credibility.

The Jackson study found that increasing compliance was associated with a statistically significant reduction in the dose of oxytocin used during labour and a reduction in the time between initiating oxytocin administration and the birth of the child.

The two maternity units in this study, despite having similar protocols on oxytocin administration, differed considerably in the rates of labour induction and augmentation, as well as in the rates of vaginal births after labour induction. Similar discrepancies among units were reported in studies from Sweden and the UK, suggesting that care offered in different units is based on clinicians' attitudes and preferences rather than on scientific research. As stated previously, the oxytocin administration regimens were not followed in 510 (93.6%) of the labours observed during our study. Although there is no scientific consensus on the optimal oxytocin administration dose or regimen, clinicians should follow their unit's guidelines unless exceptional circumstances are present.

---

### First and second stage labor management: ACOG clinical practice guideline no. 8 [^9705f84b]. Obstetrics and Gynecology (2024). High credibility.

Discontinuation of oxytocin after the active phase — In nine randomized trials (1,538 pregnant women), stopping oxytocin once the active phase was reached lowered cesarean delivery risk (9.3% vs 14.7%) (RR 0.64; 95% CI, 0.48–0.87) and uterine tachysystole (6.2% vs 13.1%) (RR 0.53; 95% CI, 0.33–0.84), but modestly increased active-phase duration (MD 27.65 minutes; 95% CI, 3.94–51.36). A Cochrane review of 10 trials found similar cesarean reduction with low-certainty evidence (RR 0.69; 95% CI, 0.56–0.86), whereas analyses restricted to participants reaching active labor showed no group difference (RR 0.92; 95% CI, 0.65–1.29); further research is needed.

---

### Oxytocin [^94bb9921]. FDA (2025). Medium credibility.

WARNINGS

Oxytocin injection (synthetic) when given for induction or stimulation of labor, must be administered only by the intravenous route and with adequate medical supervision in a hospital.

---

### European guidelines on management of arrested or protracted labor in nulliparous women [^e76de2dd]. European Journal of Obstetrics, Gynecology, and Reproductive Biology (2025). High credibility.

Regarding surgical interventions for induction of labor, more specifically with respect to amniotomy, EAPM 2025 guidelines recommend to consider performing amniotomy before administering oxytocin infusion after diagnosing arrested or protracted labor in nulliparous patients during the first stage of spontaneous labor.

---

### WHO recommendations for augmentation of labour [^45600d2c]. Geneva: World Health Organization (2014). Medium credibility.

Regarding surgical interventions for induction of labor, more specifically with respect to amniotomy, WHO 2014 guidelines recommend to perform amniotomy and administer oxytocin for treatment of confirmed delay in labor. Do not perform amniotomy alone for treatment of delay in labor.

---

### Maternal plasma levels of oxytocin during physiological childbirth-a systematic review with implications for uterine contractions and central actions of oxytocin [^0389244e]. BMC Pregnancy and Childbirth (2019). Medium credibility.

Background

Oxytocin is a key hormone in childbirth, and synthetic oxytocin is widely administered to induce or speed labour. Due to lack of synthetized knowledge, we conducted a systematic review of maternal plasma levels of oxytocin during physiological childbirth, and in response to infusions of synthetic oxytocin, if reported in the included studies.

Methods

An a priori protocol was designed and a systematic search was conducted in PubMed, CINAHL, and PsycINFO in October 2015. Search hits were screened on title and abstract after duplicates were removed (n = 4039), 69 articles were examined in full-text and 20 papers met inclusion criteria. As the articles differed in design and methodology used for analysis of oxytocin levels, a narrative synthesis was created and the material was categorised according to effects.

Results

Basal levels of oxytocin increased 3–4-fold during pregnancy. Pulses of oxytocin occurred with increasing frequency, duration, and amplitude, from late pregnancy through labour, reaching a maximum of 3 pulses/10 min towards the end of labour. There was a maximal 3- to 4-fold rise in oxytocin at birth. Oxytocin pulses also occurred in the third stage of labour associated with placental expulsion. Oxytocin peaks during labour did not correlate in time with individual uterine contractions, suggesting additional mechanisms in the control of contractions. Oxytocin levels were also raised in the cerebrospinal fluid during labour, indicating that oxytocin is released into the brain, as well as into the circulation. Oxytocin released into the brain induces beneficial adaptive effects during birth and postpartum.

Oxytocin levels following infusion of synthetic oxytocin up to 10 mU/min were similar to oxytocin levels in physiological labour. Oxytocin levels doubled in response to doubling of the rate of infusion of synthetic oxytocin.

Conclusions

Plasma oxytocin levels increase gradually during pregnancy, and during the first and second stages of labour, with increasing size and frequency of pulses of oxytocin. A large pulse of oxytocin occurs with birth. Oxytocin in the circulation stimulates uterine contractions and oxytocin released within the brain influences maternal physiology and behaviour during birth. Oxytocin given as an infusion does not cross into the mother's brain because of the blood brain barrier and does not influence brain function in the same way as oxytocin during normal labour does.

Electronic supplementary material

The online version of this article (10.1186/s12884-019-2365-9) contains supplementary material, which is available to authorized users.

---

### Pulsatile versus continuous administration of oxytocin for induction and augmentation of labor: two randomized controlled trials [^710eca22]. American Journal of Obstetrics and Gynecology (2012). Low credibility.

Objective

To determine whether pulsatile oxytocin infusion improves delivery outcome in women requiring induction or augmentation of labor.

Study Design

Two related randomized controlled trials undertaken in 2 inner-city United Kingdom university hospitals (ISRCTN72773405; http://www.isrctn.org/). Women were randomly assigned to a pulsatile or continuous infusion protocol.

Primary Outcome

cesarean section rate (induction trial); operative delivery rate (augmentation trial).

Results

For induction, cesarean section rates were similar in women receiving pulsatile (n = 264, 38.3%) vs continuous infusion of oxytocin (n = 257; 37.7%; risk ratio, 1.01; 95% confidence interval, 0.81–1.26; P = 0.903), but associated with increased "infusion to time of delivery" intervals (P < .001) in the pulsatile group. For augmentation, pulsatile infusion resulted in higher operative delivery rates (70.1%, n = 251) vs continuous infusion (62.7%, n = 249; risk ratio, 1.12; 95% confidence interval, 0.99–1.27; P = 0.077) and increased neonatal morbidity.

Conclusion

For induction, pulsatile infusion of oxytocin is effective, but conferred little clinical benefit. Pulsatile infusion is not recommended for augmentation.

---

### How effective are the components of active management of the third stage of labor? [^5c5fe127]. BMC Pregnancy and Childbirth (2013). Low credibility.

Background

Active management of the third stage of labor is recommended for the prevention of post-partum hemorrhage and commonly entails prophylactic administration of a uterotonic agent, controlled cord traction, and uterine massage. While oxytocin is the first-choice uterotonic, it is not known whether its effectiveness varies by route of administration. There is also insufficient evidence regarding the value of controlled cord traction or uterine massage. This analysis assessed the independent and combined effectiveness of all three interventions, and the effect of route of oxytocin administration on post-partum blood loss.

Methods

Secondary data were analyzed from 39202 hospital-based births in four countries and two clinical regimens: one in which oxytocin was administered following delivery of the baby; the other in which it was not. We used logistic regression to examine associations between clinical and demographic variables and post-partum blood loss ≥ 700 mL.

Results

Among those with no oxytocin prophylaxis, provision of controlled cord traction reduced hemorrhage risk by nearly 50% as compared with expectant management (P < 0.001). Among those with oxytocin prophylaxis, provision of controlled cord traction reduced hemorrhage risk by 66% when oxytocin was intramuscular (P < 0.001), but conferred no benefit when oxytocin was intravenous. Route of administration was important when oxytocin was the only intervention provided: intravenous administration reduced hemorrhage risk by 76% as compared with intramuscular administration (P < 0.001); when combined with other interventions, route of administration had no effect. In both clinical regimens, uterine massage was associated with increased hemorrhage risk.

Conclusions

Recommendations for active management of the third stage of labor should account for setting-related differences such as the availability of oxytocin and its route of administration. The optimal combination of interventions will vary accordingly.

---

### Oxytocin administration for induction and augmentation of labour in Polish maternity units-an observational study [^1a1865c1]. BMC Pregnancy and Childbirth (2021). Medium credibility.

With few exceptions, the oxytocin infusion was continued in all the observed labours, despite the national guidelines, and information in Summary of Product Characteristics for oxytocin, stating that the infusion may be discontinued when labour becomes established, i.e. when cervical dilatation reaches 5 cm. In the light of the latest reports that show the benefit of discontinuing the infusion once established labour is achieved, observed practices require further analysis. A double blind randomized controlled trial confirmed that routine discontinuation of oxytocin stimulation may lead to a small increase in the caesarean section rate but significantly reduced the risk of uterine hyperstimulation and abnormal fetal heart rate patterns. Since too few women in our test group had oxytocin discontinued after reaching active labour, we could not make similar comparisons between the groups in our study.

The guidelines for the supply of oxytocin proposed by PSOGO do not apply to particular situations such as twin pregnancies, pregnancies with previous caesarean section, pregnancies in obese women. They also lack information on the dose of oxytocin that should be set after discontinuation of infusion for the time epidural anaesthesia is provided.

Even assuming that there were situations in our study group that required non-standard behaviour, it seems unlikely that this would apply to over 90% of those surveyed.

Jackson et al. showed that the lack of adherence to oxytocin protocols resulted primarily from the insufficient consensus between care providers and the relevant literature regarding specific, restrictive dosing of oxytocin. Cooperation in building the standards and reaching the consensus may significantly improve the adherence of practice with guidelines. These findings are particularly significant for Poland, where national guidelines for oxytocin administration were issued by obstetricians only.

Our study showed that deviations from the protocol for labour augmentation were associated with increasing time interval to dose escalation. This may be due to the burden being placed on staff when caring for several labouring women at the same time and the inability to increase the dose at an exact interval. Investigating the cause of this condition, requires more investigation.

---

### Maternal and newborn plasma oxytocin levels in response to maternal synthetic oxytocin administration during labour, birth and postpartum-a systematic review with implications for the function of the oxytocinergic system [^ce3b7101]. BMC Pregnancy and Childbirth (2023). Medium credibility.

It is estimated that up to half of women giving birth in institutionalised maternity care systems, including in low- and middle-income countries, will receive synthetic oxytocin for labour induction or augmentation. In addition, routine administration of synthetic oxytocin is recommended to prevent postpartum haemorrhage after vaginal birth, either by intramuscular injection or intravenous administration. Synthetic oxytocin can also be administered by postpartum intravenous infusion to treat haemorrhage following vaginal birth or routinely after caesarean section.

With this widespread use of synthetic oxytocin in labour, birth and postpartum, it is important to review the data on oxytocin levels in connection with perinatal synthetic oxytocin administration for several reasons.

Data on maternal and newborn levels of oxytocin in response to administration of synthetic oxytocin are not readily available and there is no review summarising this data. A primary aim of this review was to summarise this data, making it understandable and accessible for clinicians and other researchers.

Another aim of this study was to illustrate that administration of synthetic oxytocin by intravenous infusion follows the expected pharmacological rules. Plasma oxytocin levels would be expected to rise in a dose-dependent way, have a well-defined half-life and achieve steady state levels after a defined period of time, analogous to what is observed after administration of other drugs. An available summary of this data might aid clinicians to ascertain the appropriate infusion rates of synthetic oxytocin during labour and postpartum and reduce the chances of adverse effects.

High infusion rates of synthetic oxytocin might result in supra-physiological oxytocin levels, which could have biological impacts for women and babies in labour. A further aim was therefore to provide data that might assist with assessing the likelihood of potential side-effects, short- or longer-term, for women administered synthetic oxytocin in the perinatal period and their offspring.

---

### Inter-institutional variations in oxytocin augmentation during labour in German university hospitals: a national survey [^58b244f5]. BMC Pregnancy and Childbirth (2019). Medium credibility.

There are a number of international and national guidelines and recommendations on oxytocin administration for labour induction and augmentation (summarised in Table 1). These include: the Irish guideline, developed by the Health Service Executive (HSE) on Oxytocin to accelerate or induce labour; the National Institute for Health and Care Excellence (NICE) guideline on Intrapartum care for healthy women and babies; the Nordic Federation of Societies of Obstetrics and Gynaecology (NFOG) guideline on Augmentation of labour; the American Congress of Obstetricians and Gynaecologists (ACOG) practice bulletin number 107 on Induction of labour, and the French recommendations on Oxytocin administration during spontaneous labour, developed by the CNGOF (French National College of Gynecologists Obstetricians) and the CNSF (National College of Midwives). These guidelines vary regarding the starting dose of international units (U) used; fluid type and volume; minimum, escalation and maximum dosages, and escalation time intervals. Most of the guidelines recommend performing an amniotomy prior to commencing an oxytocin infusion while all guidelines mention uterine hyperactivity as a contraindication for continued use. Further indications and contraindications are given together with defined criteria to start or stop oxytocin infusion during labour. Case-specific recommendations in relation to parity, uterine scars, term, preterm and twin pregnancies are usually provided.

In Germany, there are no guidelines or national data on intrapartum oxytocin augmentation. Due to the limited information, and in order to be able to contribute to a national guideline, this study aimed to describe the most common clinical practice patterns on oxytocin augmentation during labour.

---

### First and second stage labor management: ACOG clinical practice guideline no. 8 [^7db8960e]. Obstetrics and Gynecology (2024). High credibility.

Induction latent-phase labor — persistence thresholds and management are detailed as follows: In one study, 17% of pregnant women were still in the latent phase after 12 hours and 5% remained beyond 18 hours; another found that among those in latent phase longer than 12 hours who reached active labor, approximately 40% delivered vaginally. In a cohort of 10,677 nulliparous individuals undergoing induction, 96.4% reached active labor by 15 hours, and more than 40% with latent phase lasting 18 hours or more still had vaginal deliveries. If maternal and fetal status remain reassuring, cesarean delivery for failed induction in latent phase can be avoided by recommending oxytocin for at least 12–18 hours after membrane rupture before deeming induction unsuccessful, with continuation past 18 hours individualized based on clinical characteristics and patient preference.

---

### Management of spontaneous labour at term in healthy women [^a12518c7]. Journal of Obstetrics and Gynaecology Canada (2016). Medium credibility.

Regarding medical management for labor dystocia, more specifically with respect to oxytocin, SOGC 2016 guidelines recommend to titrate oxytocin augmentation to avoid tachysystole or excessive uterine activity and to produce a uterine contraction pattern of 4–5 contractions in 10 minutes (200 Montevideo units), recognizing that a minimum of 4–6 hours of adequate uterine activity may be required to achieve the desired response.

---

### Intravenous oxytocin alone for cervical ripening and induction of labour [^93c92c7b]. The Cochrane Database of Systematic Reviews (2009). Low credibility.

Background

Oxytocin is the commonest induction agent used worldwide. It has been used alone, in combination with amniotomy or following cervical ripening with other pharmacological or non-pharmacological methods.

Objectives

To determine the effects of oxytocin alone for third trimester cervical ripening and induction of labour in comparison with other methods of induction of labour or placebo/no treatment.

Search Strategy

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (January 2009) and bibliographies of relevant papers.

Selection Criteria

Randomised and quasi-randomised trials comparing intravenous oxytocin with placebo or no treatment, or with prostaglandins (vaginal or intracervical) for third trimester cervical ripening or labour induction.

Data Collection and Analysis

Two review authors independently assessed eligibility and carried out data extraction.

Main Results

Sixty-one trials (12,819 women) are included. When oxytocin inductions were compared with expectant management, fewer women failed to deliver vaginally within 24 hours (8.4% versus 53.8%, risk ratio (RR) 0.16, 95% confidence interval (CI) 0.10 to 0.25). There was a significant increase in the number of women requiring epidural analgesia (RR 1.10, 95% CI 1.04 to 1.17). Fewer women were dissatisfied with oxytocin induction in the one trial reporting this outcome (5.9% versus 13.7%, RR 0.43, 95% CI 0.33 to 0.56). Compared with vaginal prostaglandins, oxytocin increased unsuccessful vaginal delivery within 24 hours in the two trials reporting this outcome (70% versus 21%, RR 3.33, 95% CI 1.61 to 6.89). There was a small increase in epidurals when oxytocin alone was used (RR 1.09, 95% CI 1.01 to 1.17). Most of the studies included women with ruptured membranes, and there was some evidence that vaginal prostaglandin increased infection in mothers (chorioamnionitis RR 0.66, 95% CI 0.47 to 0.92) and babies (use of antibiotics RR 0.68, 95% CI 0.53 to 0.87). These data should be interpreted cautiously as infection was not pre-specified in the original review protocol. When oxytocin was compared with intracervical prostaglandins, there was an increase in unsuccessful vaginal delivery within 24 hours (50.4% versus 34.6%, RR 1.47, 95% CI 1.10 to 1.96) and an increase in caesarean sections (19.1% versus 13.7%, RR 1.37, 95% CI 1.08 to 1.74) in the oxytocin group.

Authors' Conclusions

Comparison of oxytocin with either intravaginal or intracervical PGE2 reveals that the prostaglandin agents probably increase the chances of achieving vaginal birth within 24 hours. Oxytocin induction may increase the rate of interventions in labour. A suggestion that for women with prelabour rupture of membranes induction with vaginal prostaglandin may increase risk of infection for mother and baby warrants further study.

---

### Maternal and newborn plasma oxytocin levels in response to maternal synthetic oxytocin administration during labour, birth and postpartum-a systematic review with implications for the function of the oxytocinergic system [^3ffb2a14]. BMC Pregnancy and Childbirth (2023). Medium credibility.

The women included in these older studies may have some different characteristics to modern populations, who may be older or with higher BMI. However, the pharmacological responses to synthetic oxytocin, as documented here, would not be expected to vary substantially between populations. Of interest, one included study (De Tina 2019) found no difference in oxytocin levels in response to synthetic oxytocin infusions in obese vs. non-obese women. Some studies have found longer labour, and longer duration of synthetic oxytocin infusions in women with higher BMI, but generally not higher infusion rates.

One limitation is that relatively few studies were identified, especially in some categories, making the small amount of data in these areas less robust. In addition, some studies did not clearly define dose, administration, and sample timings, and control groups were not always included.

A major strength of this review and methodology is the collating of all available numerical data on maternal and newborn oxytocin levels in response to maternal synthetic oxytocin administration. This has facilitated data-based pharmacological calculations of infusion rates, the total doses administered to labouring women and the resulting oxytocin levels. This data can then be compared with data from other clinical studies, and with levels in physiological labour. These comparisons can also inform clinicians in establishing thresholds in dosage and pharmacological effects that may exceed physiological parameters and potentially over-ride maternal and/or fetal adaptations. The infusion rates seen in this review are similar to those recommended in modern maternity-care guidelines and protocols, as discussed.

This hard data and calculations also provide important and unique perspectives on comparative dose-exposures for animal offspring. Calculations in this review show that dose-exposures in current animal studies, whether administered to the pregnant female or to the newborn, are many-fold higher than safe human exposures for the pregnant woman or her fetus/newborn. This adds important caveats to the interpretation of current animal models of synthetic oxytocin exposure, including in relation to possible long-term impacts. These considerations are also underlined by the included human data on newborn oxytocin levels, which did not rise in response to maternal synthetic oxytocin administration.

---

### High and low dose oxytocin in augmentation of labor [^570af62d]. International Journal of Gynaecology and Obstetrics (2004). Low credibility.

Objective

To compare the efficacy and safety of high dose oxytocin in the augmentation of labor.

Method

Two hundred pregnant women requiring augmentation of labor were randomly assigned to receive oxytocin by either a low dose protocol (1.5 microm/min initially, increased by 1.5 microm/min every 30 min) or a high dose protocol (4.5 microm/min initially, increased by 4.5 microm/min every 30 min).

Results

High dose of oxytocin was associated with a significant shortening of labor 4 (1.10–10) vs. 6 (1–10) h, p < 0.0001 without a significant difference in cesarean delivery rate, neonatal and maternal outcome.

Conclusion

The use of high dose oxytocin is associated with significantly shorter labor without any adverse fetal and maternal effects.

---

### Oxytocin administration for induction and augmentation of labour in Polish maternity units-an observational study [^27ce8592]. BMC Pregnancy and Childbirth (2021). Medium credibility.

Background

There is not enough data regarding practices and protocols on the dose of oxytocin administrated to women during labour. Empirical evidence indicates that compliance with the guidelines improves the quality of healthcare and reduces adverse effects. The study aimed to evaluate practices of oxytocin provision for labour induction and augmentation in two maternity units in Poland.

Methods

The article presents a prospective observational study. Data from 545 (n = 545) labours was collected in two maternity units. First, the total dose (the total amount of oxytocin provided from the beginning in the labour ward until delivery including the III and IV stage of labour) and cumulative dose of oxytocin (the amount of oxytocin given until the birth of the neonate) administered to women during labour was calculated. Then, the relationship between the cumulative dose of oxytocin and short term perinatal outcomes (mode of delivery, use of epidural anaesthesia, Apgar scores, birth weight and postpartum blood loss) was analysed. Finally, the compliance of oxytocin supply during labour with national guidelines in the following five criteria: medium, start dose, escalation rate, interval, the continuation of infusion after established labour was examined.

Results

The average cumulative dose of oxytocin administrated to women before birth was 4402 mU following labour induction and 2366 mU following labour augmentation. The actual administration of oxytocin deviated both from the unit and national guidelines in 93.6% of all observed labours (mainly because of continuation of infusion after established labour). We found no statistically significant correlation between the cumulative dose of oxytocin administered and mode of delivery, immediate postpartum blood loss or Apgar scores. There was no observed effect of cumulative dose oxytocin on short-term perinatal outcomes. The two units participating in the study had similar protocols and did not differ significantly in terms of total oxytocin dose, rates of induction and augmentation - the only observed difference was the mode of delivery.

Conclusions

The study showed no effect of the mean cumulative oxytocin dose on short-term perinatal outcomes and high rate of non-compliance of the practice of oxytocin administration for labour induction and augmentation with the national recommendations. Cooperation between different professional groups of maternity care providers should be considered in building national guidelines for maternity care. Further studies investigating possible long-term effects of the meant cumulative dose of oxytocin and the reasons for non-compliance of practice with guidelines should be carried out.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12884-021-04190-w.

---

### Oxytocin regimen used for induction of labor and pregnancy outcomes [^594e5df2]. American Journal of Obstetrics & Gynecology MFM (2024). Medium credibility.

Background

Following the results of the A Randomized Trial of Induction Versus Expectant Management trial, which demonstrated a reduction in cesarean delivery with no increase in adverse perinatal outcomes after elective induction of labor in low-risk nulliparous patients at 39 weeks of gestation compared with expectant management, the use of induction of labor has increased. Current evidence is insufficient to recommend mid- to high-dose regimens over low-dose regimens for routine induction of labor.

Objective

This study aimed to evaluate the association between oxytocin regimen and cesarean delivery and an adverse perinatal composite outcome in low-risk nulliparous patients undergoing induction of labor at ≥ 39 weeks of gestation.

Study Design

This was a secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network's A Randomized Trial of Induction Versus Expectant Management randomized trial. Patients who received a mid- to high-dose oxytocin regimen (starting or incremental increase > 2 mU/min) were compared with those who received a low-dose oxytocin regimen (starting and incremental increase ≤ 2 mU/min). The co-primary outcomes for this secondary analysis were (1) cesarean delivery and (2) composite of perinatal death or severe neonatal complications. Multivariate Poisson regression was used to estimate adjusted relative risks and 97.5% confidence intervals for the co-primary endpoints and 95% confidence intervals for binomial outcomes, and multinomial logistic regression was used to estimate adjusted odds ratios and 95% adjusted relative risks for multinomial outcomes.

Results

Of 6106 participants enrolled in the primary trial, 2933 underwent induction of labor with oxytocin: 861 in the mid- to high-dose group and 2072 in the low-dose group. The lower frequency of cesarean delivery in the mid- to high-dose group than in the low-dose group (20.3% vs 25.2%, respectively; relative risk, 0.81; 95% confidence interval, 0.69–0.94) was not significant after adjustment (adjusted relative risk, 0.90; 97.5% confidence interval, 0.76–1.07). The composite of perinatal death or severe neonatal complications was more frequent in the mid- to high-dose group than in the low-dose group (6.7% vs 4.3%, respectively; relative risk, 1.55; 95% confidence interval, 1.13–2.14) and remained significant after adjustment (adjusted relative risk, 1.61; 97.5% confidence interval, 1.11–2.35). Most cases in the composite were from the respiratory support (5.2% in the mid- to high-dose group vs 3.1% in the low-dose group) component, with an increase in transient tachypnea in newborns (3.8% in the mid- to high-dose group vs 2.5% in the low-dose group; adjusted relative risk, 1.63; 95% confidence interval, 1.04–2.54). The duration of neonatal respiratory support for 1 day was significantly longer in the mid- to high-dose group than in the low-dose group (3.5% vs 1.4%, respectively; adjusted relative risk, 2.59; 95% confidence interval, 1.52–4.39). However, support beyond 1 day was not different between the 2 groups. Compared with the low-dose group, the mid- to high-dose group had a higher operative vaginal delivery rate (10.0% vs 7.0%, respectively; adjusted relative risk, 1.54; 95% confidence interval, 1.18–2.00) and shorter duration of time from start of oxytocin to delivery (crude median: 12 hours [interquartile range, 8–17] vs 13 hours [interquartile range 9–19], respectively; adjusted median difference: -2 [95% CI, -2 to -1]; P < .001).

Conclusion

The use of mid-to high-dose oxytocin regimens for induction of labor in nulliparas at ≥ 39 weeks of gestation was not associated with a lower cesarean delivery rate or improved neonatal outcomes compared with the use of low-dose oxytocin regimens. Although the use of mid- to high-dose oxytocin regimens was associated with a shorter duration of labor, there was an increase in self-limited neonatal respiratory support and no difference in cesarean delivery rates. More evidences are needed to define the magnitude of potential maternal and neonatal benefits and risks associated with oxytocin regimens.

---

### Methods of induction of labour: a systematic review [^0735ca96]. BMC Pregnancy and Childbirth (2011). Low credibility.

Oxytocin

Our search identified one Cochrane systematic review which included 61 trials with 12,819 women and evaluated oxytocin for induction of labour. Comparisons were made between intravenous (IV) oxytocin versus placebo/expectant management (25 trials, 6660 women), IV oxytocin versus vaginal prostaglandin (PGE2) (27 trials, 4564 women), IV oxytocin versus intracervical prostaglandins (PGE2) (14 trials, 1331 women), and IV oxytocin versus vaginal PGF2α (3 trials, 291 women).

Three trials including 399 women reported that IV oxytocin, when compared with expectant management, reduced failure to achieve vaginal delivery within 24 hours (16/191 versus 112/208; RR 0.16, 95% CI 0.10 to 0.25; NNT = 3). Meta-analysis of 24 trials including 6620 women found a small but statistically significant increased rate of caesarean delivery for women in the oxytocin group (339/3267 versus 301/3353; RR 1.17, 95% CI 1.01 to1.35; NNH = 66). There was no significant difference in uterine hyperstimulation with or without FHR changes. Use of oxytocin significantly reduced chorioamnionitis (14 studies, 5514 women 144/2720 versus 213/2795; RR 0.69, 95% CI 0.57 to 0.85; NNT = 40); however there was significant heterogeneity among the included trials for this comparison, (I 2 = 65%, P = 0.001) and the authors' analysis of the studies included in this comparison using the random effects method was not statistically significant. Likewise, NICU admissions were reduced by oxytocin compared to placebo or expectant management, (7 studies, 4387 women, 264/2196 versus 333/2191; RR 0.79, 95% CI 0.68 to 0.92, NNT = 32). However, there was significant between study heterogeneity for this comparison (I 2 = 70%, P = 0.0003) and this result was no longer statistically significant when the random effects method was used for analysis. The majority of the studies included in these comparisons required ruptured membranes for entry, likely influencing this result. Data were insufficient to establish conclusions regarding neonatal and maternal mortality or serious morbidity.

---

### Oxytocin [^94f01e34]. FDA (2025). Medium credibility.

Pregnancy Category C.

There are no known indications for use of oxytocin in the first and second trimester of pregnancy other than in relation to spontaneous or induced abortion. Based on the wide experience with this drug and its chemical structure and pharmacological properties, it would not be expected to present a risk of fetal abnormalities when used as indicated.

Nonteratogenic Effects — See ADVERSE REACTIONS in the fetus or infant.

Labor and Delivery — See INDICATIONS AND USAGE.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when oxytocin is administered to a nursing woman.

---

### Highlights of prescribing information… [^82f4dca2]. FDA (2025). Medium credibility.

- Instruct patients to take tablets one at a time, with enough water to ensure complete swallowing immediately after placing in mouth.
- Do not abruptly discontinue OXYCONTIN in a physically dependent patient. Adults: For opioid-naïve and opioid non-tolerant patients, initiate with 10 mg.
- Monitor patients closely for respiratory depression, especially within the first 24–72 hours of initiating therapy and following dosage increases with OXYCONTIN and adjust the dosage accordingly. Instruct patients to swallow OXYCONTIN tablets whole, one tablet at a time, with enough water. Treatment with OXYCONTIN can be initiated after the transdermal fentanyl patch has been removed for at least 18 hours. Although there has been no systematic assessment of such conversion, start with a conservative conversion: substitute 10 mg of OXYCONTIN every 12 hours for each 25 mcg per hour fentanyl transdermal patch. Follow the patient closely during.

pediatric patients 11 years and older. If switching from transdermal fentanyl patch to OXYCONTIN, ensure that the patch has been removed for at least 18 hours prior to starting OXYCONTIN. Although there has been no systematic assessment of such conversion, start with a conservative conversion: substitute 10 mg of OXYCONTIN every 12 hours for each 25 mcg. patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both. Do not abruptly discontinue OXYCONTIN. and phenytoin, in OXYCONTIN-treated patients may increase oxycodone plasma concentrations and prolong opioid adverse reactions.

When using OXYCONTIN with CYP3A4 inhibitors or discontinuing CYP3A4 inducers in OXYCONTIN-treated patients, monitor patients closely at frequent intervals and consider dosage reduction of OXYCONTIN until stable drug effects are.

---

### First and second stage labor management: ACOG clinical practice guideline no. 8 [^a27f8e6e]. Obstetrics and Gynecology (2024). High credibility.

High-dose compared with low-dose oxytocin regimens — A systematic review defined high-dose oxytocin as at least 100 milliunits in the first 40 minutes with increments delivering at least 60 milliunits in the first 2 hours, versus low-dose oxytocin as less than 100 milliunits in the first 40 minutes with increments delivering less than 600 milliunits total in the first 2 hours; primary outcomes revealed no significant differences.

---

### Efficacy and safety of misoprostol versus oxytocin for labor induction in women with prelabor rupture of membranes: a meta-analysis [^31ad7723]. BMC Pregnancy and Childbirth (2025). Medium credibility.

Background

Prelabor rupture of membranes (PROM) complicates 8% of pregnancies, often necessitating labor induction to prevent maternal and neonatal complications. Misoprostol, a cost-effective prostaglandin, has been proposed as an alternative to oxytocin for labor induction in PROM cases, but its efficacy and safety remain debated.

Methods

The PubMed, Web of science, Embase, Google scholar, ClinicalTrials.gov, and Cochrane Library databases were searched on January 25, 2025. Randomized controlled trials (RCTs) comparing misoprostol and oxytocin for labor induction in term PROM were eligible. The primary outcomes were vaginal birth within 24 h and the induction to delivery interval. Secondary outcomes included the duration of second stage of labor, the induction to active labor, cesarean section, postpartum hemorrhage (PPH), and other maternal/neonatal complications.

Results

Data from 20 RCTs involving 2,980 participants were analyzed. Misoprostol significantly reduced the induction-to-delivery interval and the duration of the second stage of labor compared to oxytocin (WMD = -62.82, 95% CI (-110.56, -15.08); WMD = -4.29, 95% CI (-8.05, -0.52), respectively). It also lowered the risk of PPH (OR = 0.63, 95% CI (0.41, 0.98)). However, no significant differences were found in other outcomes between misoprostol and oxytocin.

Conclusions

Misoprostol is a viable alternative to oxytocin for labor induction in PROM, offering shorter labor durations and reduced PPH risk without compromising maternal and neonatal outcomes. Further researches are needed to optimize dosing, administration routes, and assess maternal satisfaction.

---

### CONDISOX-continued versus discontinued oxytocin stimulation of induced labour in a double-blind randomised controlled trial [^9458d159]. BMC Pregnancy and Childbirth (2019). Medium credibility.

Randomisation, blinding and informed consent

Women will be informed of the trial when induction of labour is planned or at the first visit to the labour ward in case of prelabour rupture of membranes. Subjects' signed informed consent to participation will be obtained prior to randomisation and intervention (i.e. before any oxytocin stimulation).

Women will be randomised in a 1:1 ratio to either the continued oxytocin group or the discontinued oxytocin group using an Internet-based randomisation programme (Trialpartner). Random block-sizes of four will be used, and the women will be stratified by site, parity (nulliparous or parous +/− previous caesarean) and indication for oxytocin infusion (induction of labour or induction due to prelabour rupture of membranes (PROM)). The randomisation number generated by the computer programme corresponds to number of the studymedication (masked, identical ampoules). The personnel of the delivery ward will administer the medication according to existing guidelines concerning administration. Women, caregivers, and trialmanagers will be blinded to the allocation due to the use of identical study medication preparations.

Complications

In accordance with guidelines The infusion will be reduced or discontinued at any point of labour, if the following occur:
Tachysystole (> 5 contractions per 10 min, averaged over a 30-min window)
Uterine contractions lasting 2 min or more
Non-reassuring CTG (recurrent variable decelerations, fetal tachycardia or bradycardia, minimal to absent baseline variability, late decelerations) or significant STAN event(s)
Suspicion of uterine rupture

Dystocia

If there is failure to progress, defined as less than two cm dilation over 4 h despite apparently adequate contractions, and/or maximal infusion rates (oxytocin or placebo), the study medication can be replaced with open-labelled oxytocin infusion.

If failure to progress persists, despite open-labelled oxytocin infusion for 4 h, caesarean section can be considered.

---

### Maternal and newborn plasma oxytocin levels in response to maternal synthetic oxytocin administration during labour, birth and postpartum-a systematic review with implications for the function of the oxytocinergic system [^8a2cf21c]. BMC Pregnancy and Childbirth (2023). Medium credibility.

Study design and other methodological considerations

The studies in this review are exploratory studies describing pharmacological and biological responses to the administration of synthetic oxytocin during the major physiological processes of labour and birth, rather than randomised controlled trials to ascertain the outcome of a clinical intervention. However, these included studies are of high quality and are very valuable in illustrating pharmacological and physiological processes.

Labour is a long biological process with an unpredictable rate of progress and is therefore difficult to study. There is a high variability in individual endogenous oxytocin levels, partly due to the pulsatile release of oxytocin during labour. This makes it necessary to take multiple blood samples, which involves ethics and expense, especially for high-quality RIA assays. The majority of included studies involve repeated samples analysed with the same well-validated RIA technique. (See previous systematic review for a more thorough discussion of methodological considerations in relation to plasma oxytocin sampling in labour).

In relation to randomisation, it is difficult to standardise the administration of synthetic oxytocin through the course of labour because infusion rates must be individually adjusted to accommodate clinical factors such as labour progress, pain, and fetal tolerance. Co-interventions such as epidural analgesia may also impact maternal plasma oxytocin levels in labouring women. (The effects of epidural analgesia on maternal and newborn plasma oxytocin levels will be reported in an upcoming systematic review.) Therefore, a randomised trial of synthetic oxytocin at different dosages in labouring women would be problematic and unlikely to provide cohesive data. It is noteworthy that the only study in this review in which dosage of synthetic oxytocin was randomised occurred in the well-controlled post-caesarean context.

Intrapartum synthetic oxytocin: maternal dose and oxytocin assays

The studies identified in this review are generally older, but the dose-regimens and infusion rates are similar to those used in current maternity care, as discussed below. This makes the maternal plasma oxytocin levels obtained in this review relevant to contemporary settings.

In the reviewed studies, starting rates were 1–3 mU/min, increasing to maximum 32 mU/min. Total doses of synthetic oxytocin administered during labour, reflecting infusion rate and duration, ranged from 0.5–15 IU, as stated in the studies or calculated from the data, based on maximum infusion rates continued for 8 hours (see Table 5). These calculated values are likely overestimated, as infusions are usually started at low rates and titrated upwards only when necessary.

---

### First and second stage labor management: ACOG clinical practice guideline no. 8 [^0878b48a]. Obstetrics and Gynecology (2024). High credibility.

Oxytocin infusion protocols (Table 3) — low-dose and high-dose regimens are outlined as follows: low-dose starting dose 0.5–2 mU/min with incremental increase 1–2 mU/min at 15–40 min intervals; high-dose starting dose 4 or higher mU/min with incremental increase 3–6 mU/min at 15–40 min intervals. In nulliparous women, the Agency for Healthcare Research and Quality (AHRQ) 2020 systematic review determined that high-dose oxytocin is associated with a lower cesarean delivery rate compared with low-dose oxytocin protocols, with no difference in maternal hemorrhage. Current research suggests no significant differences in maternal or neonatal outcomes with different oxytocin dosing regimens; therefore, either low-dose or high-dose oxytocin strategies are reasonable approaches to the active management of labor to reduce operative deliveries, and a maximum dose of oxytocin has not been established.

---

### Oxytocin administration for induction and augmentation of labour in Polish maternity units-an observational study [^e3bf5a5d]. BMC Pregnancy and Childbirth (2021). Medium credibility.

In our study, 84% of women birthed vaginally following labour augmentation, similar to the proportion of 87% found in a Danish study but considerable higher than the 51% reported in Bugg et al.'s (2005) study with nulliparous women.

We did not find any correlation between the mean cumulative dose of oxytocin administrated to women and the mode of delivery. Similar findings were reported in studies comparing the high, and low-dose augmentation, where the higher doses of oxytocin administrated did not lower the risk of CS. A systematic review concluded that early administration of oxytocin did not affect the mode of birth. However, some studies have demonstrated a correlation between oxytocin administration and mode of delivery, including a lower risk of CS when compared to expectant management but overall higher risk of intrapartum interventions. Systematic reviews show that high-dose inductions and high-dose augmentation did not affect caesarean section rates. We were unable to find any other studies reporting on the correlation between the cumulative dose of oxytocin administered and mode of birth.

Ours findings revealed that most hospitals in Warsaw did not have written protocols on intrapartum oxytocin administration for induction or augmentation of labour. Even in units where protocols were available and compliant with the national guidelines, the actual administration of oxytocin did not follow the recommended regimen in 94% of observed labours.

While one study conducted in Germany found that 69% of participating units had protocols on oxytocin administration, they did not explore actual adherence to the protocol. The study by Jackson showed that establishing a collaboration between various care providers to build a consensus-driven, evidence-based approach to the use of oxytocin resulted in a significant increase (from 73 to 100%) of adherence of practice to the guidelines. Studies showed that the use of oxytocin in accordance with guidelines was associated with several significant clinical outcomes, including a decrease in caesarean births for foetal distress based on electronic foetal monitoring, decreases in the length of the first stage of labour, and the decrease in the maximum dose of oxytocin.

---

### High dose and low dose oxytocin regimens as determinants of successful labor induction: a multicenter comparative study [^f716f663]. BMC Pregnancy and Childbirth (2020). Medium credibility.

Background

Induction of labor (IOL) refers to the iatrogenic stimulation of uterine contractions before the onset of spontaneous labor to accomplish vaginal delivery (VD). Use of Oxytocin for labor induction is one of the most frequently used medications in obstetrics. This synthetic polypeptide hormone has been used to stimulate uterine contractions since 1950s after synthesized for the first time in 1953 by Vincent du Vigneaud.

Oxytocin regimen can be classified as high-dose or low-dose based on different parameters. These are amount of starting dose, rate of incremental dose and intervals of escalation. The high-dose regimens varied across the different trials; starting doses ranged from 4 to 10 mili-unit/minute (mU/min), with increases in dose ranging from 4 to 7 mU/min and maximum rates ranging from 4 to 90 mU/min. The Low-dose regimen commences infusion at a range of 1–4 mU/min, with rate increases ranging from 1 to 2 mU/min and maximum rates ranging between 1 and 32 mU/min as mentioned in one systematic review. Intervals of escalation of oxytocin doses vary from 15 to 60 min across the trials.

Worldwide, there was neither agreement on standard oxytocin regimen nor strong evidence to recommend a particular dosage of oxytocin regimen for labor induction. However, one meta-analysis conducted in 1998 supports the use of a low-dose oxytocin infusion for IOL. In Ethiopia, although very few studies were conducted to assess rate and determinants of induction success, there was no comparative study done to evaluate the effects of the two oxytocin regimens on success of induction. This study was, therefore aimed at comparing the effects of these oxytocin regimens on success of labor induction.

---

### Reducing neonatal morbidity by discontinuing oxytocin during the active phase of first stage of labor: a multicenter randomized controlled trial STOPOXY [^35bff0e6]. BMC Pregnancy and Childbirth (2020). Medium credibility.

Oxytocin infusion protocol and randomization

During the latent phase, oxytocin is administered according to national guidelines, i.e. low dose oxytocin infusion of less than 4 mUI/min with increments every 30 min, without exceeding a 20 mUI/min flow rate.

Women are included and randomized in two groups before 6 cm, during the latent phase (Supplementary Material 1):
The experimental group corresponds to discontinuation of oxytocin at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion is stopped beyond a cervical dilation equal or greater than 6 cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 h of labor arrest (no progression of the cervical dilation and no progression of the fetal head).
The control group corresponds to the standard care in France, i.e. when oxytocin is started during the latent phase of the 1st stage administration of oxytocin is continued during the active 1st stage and during the 2nd stage if the fetal heart rate is reassuring. As in French standard practice, the oxytocin infusion is maintained with no increments if cervical dilation progresses. If needed (abnormal fetal heart rate, uterine hyperstimulation) the infusion can be stopped.

The randomization is computerized and accessible 24 h on line. Subjects are distributed between the two groups at a ratio of 1:1. The randomization is stratified on the center and parity (nullipara/multipara). The stratification by center will allow considering the possible variations of practices between centers during labor or delivery (e.g. modalities of epidural analgesia, type of analgesic products used, etc.). Specific information on the practices is also collected in the electronic case report form (e-CRF). The stratification by parity is needed because multiparous and nulliparous women differ on several secondary endpoints such as duration of labor and mode of delivery.

Among women included in the STOPOXY trial, some will have a spontaneous labor and others an induction of labor including induction by oxytocin only or cervical ripening. Induction protocols and particularly cervical ripening methods (Prostaglandins E1, Prostaglandins E2, and mechanical methods) could differ between centers but this potential difference will be taken into account by the stratification by center.

Each change in dose of oxytocin (increments) after 6 cm of cervical dilation and until delivery will be prospectively collected and reported by the midwife or obstetrician on a specific form. The time, type of modification of infusion, reason for the change, cervical dilation and oxytocin flow will be specified.

---

### Oxytocin [^ebefaa4f]. FDA (2025). Medium credibility.

DOSAGE AND ADMINISTRATION

Dosage of oxytocin is determined by uterine response. The following dosage information is based upon the various regimens and indications in general use.

Induction or Stimulation of Labor

Intravenous infusion (drip method) is the only acceptable method of administration for the induction or stimulation of labor.

Accurate control of the rate of infusion flow is essential. An infusion pump or other such device and frequent monitoring of strength of contractions and fetal heart rate are necessary for the safe administration of oxytocin for the induction or stimulation of labor. If uterine contractions become too powerful, the infusion can be abruptly stopped, and oxytocic stimulation of the uterine musculature will soon wane.

An intravenous infusion of a non-oxytocin containing solution should be started. Physiologic electrolyte solutions should be used except under unusual circumstances.

To prepare the usual solution for intravenous infusion–one mL (10 units) is combined aseptically with 1,000 mL of a non-hydrating diluent.

The combined solution, rotated in the infusion bottle to insure thorough mixing, contains 10 mU/mL. Add the container with dilute oxytocic solution to the system through the use of a constant infusion pump or other such device to control accurately the rate of infusion.

The initial dose should be no more than 1 to 2 mU/min. The dose may be gradually increased in increments of no more than 1 to 2 mU/min., until a contraction pattern has been established which is similar to normal labor.

The fetal heart rate, resting uterine tone, and the frequency, duration, and force of contractions should be monitored.

The oxytocin infusion should be discontinued immediately in the event of uterine hyperactivity or fetal distress. Oxygen should be administered to the mother. The mother and fetus must be evaluated by the responsible physician.

Control of Postpartum Uterine Bleeding

Intravenous Infusion (Drip Method) — To control postpartum bleeding, 10 to 40 units of oxytocin may be added to 1,000 mL of a nonhydrating diluent and run at a rate necessary to control uterine atony.

Intramuscular Administration — 1 mL (10 units) of oxytocin can be given after delivery of the placenta.

Treatment of Incomplete or Inevitable Abortion

Intravenous infusion with physiologic saline solution, 500 mL, or 5% dextrose in physiologic saline solution to which 10 units of oxytocin have been added should be infused at a rate of 20 to 40 drops/minute.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

---

### WHO recommendations on mechanical methods for induction of labour [^43edb98f]. Geneva: World Health Organization (2022). High credibility.

Regarding therapeutic procedures for induction of labor, more specifically with respect to balloon catheter, WHO 2022 guidelines recommend to offer the combination of balloon catheter plus oxytocin administration for induction of labor.

---

### Dystocia in nulliparous women [^3e728333]. American Family Physician (2007). Low credibility.

Dystocia is common in nulliparous women and is responsible for more than 50 percent of primary cesarean deliveries. Because cesarean delivery rates continue to rise, physicians providing maternity care should be skilled in the diagnosis, management, and prevention of dystocia. If labor is not progressing, inadequate uterine contractions, fetal malposition, or cephalopelvic disproportion may be the cause. Before resorting to operative delivery for arrested labor, physicians should ensure that the patient has had adequate uterine contractions for four hours, using oxytocin infusion for augmentation as needed. For nulliparous women, high-dose oxytocin-infusion protocols for labor augmentation decrease the time to delivery compared with low-dose protocols without causing adverse outcomes. The second stage of labor can be permitted to continue for longer than traditional time limits if fetal monitoring is reassuring and there is progress in descent. Prevention of dystocia includes encouraging the use of trained labor support companions, deferring hospital admission until the active phase of labor when possible, avoiding elective labor induction before 41 weeks' gestation, and using epidural analgesia judiciously.

---

### Reduced risk of cesarean delivery with oxytocin discontinuation in active labor: a systematic review and meta-analysis [^390f224d]. American Journal of Obstetrics and Gynecology (2025). Medium credibility.

Objective

Our objective was to determine if oxytocin discontinuation in the active phase of labor impacts the rate of cesarean delivery compared to continuation of oxytocin.

Data Sources

This study was a systematic review and meta-analysis of randomized controlled trials. A research librarian performed a database search using a combination of standardized terms and keywords related to oxytocin discontinuation and stages of labor from database inception until February 2024. This protocol was registered in The International Prospective Register of Systematic Reviews (PROSPERO).

Study Eligibility Criteria

Randomized controlled trials of pregnant patients who received oxytocin for induction or augmentation of labor, whose outcomes compared discontinuation and continuation of oxytocin in active labor, were included. We defined "active phase of labor" as defined by each trial. Nonrandomized trials, quasi-randomized trials, and animal models were excluded. The primary outcome was the rate of cesarean delivery. Secondary maternal outcomes included postpartum hemorrhage, total blood loss, and infectious outcomes. Secondary neonatal outcomes included Apgar score at 5 minutes < 7, umbilical arterial pH < 7.10, neonatal therapeutic hypothermia, neonatal intensive care unit admission, neonatal resuscitation at birth, and neonatal death.

Study Appraisal and Synthesis Methods

The risk of bias in each study was assessed using the guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions. Heterogeneity was measured using Higgins I 2. Meta-analysis was performed in Review Manager 5.4.1 and StataSE 16 to determine summary treatment effects in terms of relative risk or mean difference with 95% confidence intervals. The adherence of each included trial to the trustworthiness criteria outlined by the OBGYN Editors' Integrity Group was assessed, and a leave-1-out analysis was performed to evaluate the effect of studies with concerns regarding trustworthiness.

Results

Fifteen randomized controlled trials, including 5734 patients, were ultimately included in the meta-analysis. The rate of cesarean delivery, reported in 13 studies, was lower with discontinuation of oxytocin in the active phase of labor (relative risk = 0.80; 95% confidence interval, 0.66–0.97; 95% prediction interval, 0.38–1.22). Discontinuation of oxytocin was also associated with a lower risk of uterine tachysystole (relative risk = 0.45; 95% confidence interval, 0.34–0.60; I 2, 26%), and nonreassuring fetal heart rate tracing (relative risk = 0.64; 95% confidence interval, 0.49–0.82; I 2, 41%). Discontinuation of oxytocin increased the duration of active labor by an average of 30 minutes and second stage of labor by an average of 6 minutes.

Conclusion

Although associated with an extension of labor by half an hour, discontinuation of oxytocin in the active phase of labor was associated with a 20% decreased risk of cesarean delivery and a lower risk of uterine tachysystole and nonreassuring fetal heart rate tracing. While the pooled analysis suggests a beneficial effect, this finding is dependent on the inclusion of studies with concerns regarding trustworthiness.

---

### Maternal plasma levels of oxytocin during physiological childbirth-a systematic review with implications for uterine contractions and central actions of oxytocin [^03d64c00]. BMC Pregnancy and Childbirth (2019). Medium credibility.

Levels and effects after infusion of synthetic oxytocin

While the use of synthetic oxytocin was not initially the subject of this review, some of the included studies measured oxytocin levels when synthetic oxytocin was infused. In view of the widespread use of synthetic oxytocin for induction and augmentation of labour, we decided to include this information.

Infusions of synthetic oxytocin for induction or augmentation of labour are generally commenced at a low rate of around 1–3 mU/min, with the dose either increased step-wise (arithmetic) or doubled (geometric) at 15–40 min intervals, although protocols vary widely. Generally the maximum dose of synthetic oxytocin does not exceed 32 mU /min.

One of the included studies found that, when synthetic oxytocin was infused in doses up to 9 mU/min, maternal plasma levels of oxytocin were similar to those observed during physiological labour whereas doses around 10–16 mU/min gave rise to levels that were approximately double those of physiological labour (Fig. 3 a & b). This implies that the concentrations obtained following infusion rates over 16 mU/min exceeds physiological levels. A steady state concentration was found by 40 min after a change in infusion rate. It is of interest that administration of a bolus as low as 4–8 mU of synthetic oxytocin gave rise to uterine contractions in women at term, with an elevation of oxytocin levels comparable to levels obtained during a physiological pulse in labour.

In contrast to the episodic, narrow peaks of oxytocin in physiological labour, administration of synthetic oxytocin produced flat oxytocin levels in maternal blood. These flat levels may influence the pattern of uterine contractions and contribute to the hyperstimulation that can result from high doses of synthetic oxytocin. Excessive uterine activity may also compromise fetal blood supply, causing hypoxia.

In addition, prolonged exposure to synthetic oxytocin may eventually lead to reduced contractility of the uterine muscles due to desensitization of oxytocin receptors. The decreased efficacy of oxytocin may also increase the risk of postpartum haemorrhage. In addition, the high levels of lactate that accumulate in uterine muscle, and hypoxia due to excessive uterine contractions, may also contribute to these risks.

The pharmacokinetics of oxytocin during labour are surprisingly poorly studied. As studied in non-pregnant women, synthetic oxytocin is degraded according to a two-compartment model. However in labour, the levels of oxytocinases, the enzymes that degrade oxytocin, increase 10- to 20-fold, which may also influence the degradation of oxytocin and thereby the half-life and metabolic clearance rate of oxytocin.

---

### ACOG practice bulletin no. 205: vaginal birth after cesarean delivery [^33076725]. Obstetrics and Gynecology (2019). High credibility.

ACOG Practice Bulletin No. 205 — Induction and augmentation of labor during trial of labor after cesarean (TOLAC) outline uterine rupture risks by labor method and oxytocin use. Reported rupture rates include 0.52% for spontaneous labor, 0.77% for labor induced without prostaglandins, and 2.24% for prostaglandin-induced labor. In a multicenter TOLAC cohort (n = 33,699), rupture risks were 1.4% for induction with prostaglandins with or without oxytocin, 1.1% for oxytocin alone, 0.9% for augmented labor, and 0.4% for spontaneous labor, and a secondary analysis of 11,788 women found increased rupture only among those induced without a prior vaginal delivery (1.5% versus 0.8%, P = 0.02). Uterine rupture was no more likely when induction occurred with an unfavorable cervix than with a favorable cervix. A separate analysis noted a dose–response effect between higher maximum oxytocin dose and increased rupture risk, yet studies have not identified a clear threshold for rupture and an upper limit for oxytocin dosage with TOLAC has not been established. Given that study results vary and the absolute magnitude of reported risk is small, oxytocin augmentation may be used in women attempting TOLAC.

---

### Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care [^8e5f9cb4]. The Cochrane Database of Systematic Reviews (2013). Low credibility.

Background

Caesarean section rates are over 20% in many developed countries. The main diagnosis contributing to the high rate in nulliparae is dystocia or prolonged labour. The present review assesses the effects of a policy of early amniotomy with early oxytocin administration for the prevention of, or the therapy for, delay in labour progress.

Objectives

To estimate the effects of early augmentation with amniotomy and oxytocin for prevention of, or therapy for, delay in labour progress on the caesarean birth rate and on indicators of maternal and neonatal morbidity.

Search Methods

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 May 2013), MEDLINE (1966 to 4 July 2013), Embase (1980 to 4 July 2013), CINAHL (1982 to 4 July 2013), MIDIRS (1985 to 4 July 2013) and contacted authors for data from unpublished trials.

Selection Criteria

Randomized and quasi-randomized controlled trials that compared oxytocin and amniotomy with expectant management.

Data Collection and Analysis

Three review authors extracted data independently. We stratified the analyses into 'Prevention Trials' and 'Therapy Trials' according to the status of the woman at the time of randomization. Participants in the 'Prevention Trials' were unselected women, without slow progress in labour, who were randomized to a policy of early augmentation or to routine care. In 'Treatment Trials' women were eligible if they had an established delay in labour progress.

Main Results

For the 2013 update, we identified and excluded one new clinical trial. This updated review includes 14 trials, randomizing a total of 8033 women. The unstratified analysis found early intervention with amniotomy and oxytocin to be associated with a modest reduction in the risk of caesarean section; however, the confidence interval (CI) included the null effect (risk ratio (RR) 0.89; 95% CI 0.79 to 1.01; 14 trials; 8033 women). In prevention trials, early augmentation was associated with a modest reduction in the number of caesarean births (RR 0.87; 95% CI 0.77 to 0.99; 11 trials; 7753). A policy of early amniotomy and early oxytocin was associated with a shortened duration of labour (average mean difference (MD) - 1.28 hours; 95% CI -1.97 to -0.59; eight trials; 4816 women). Sensitivity analyses excluding four trials with a full package of active management did not substantially affect the point estimate for risk of caesarean section (RR 0.87; 95% CI 0.73 to 1.05; 10 trials; 5165 women). We found no other significant effects for the other indicators of maternal or neonatal morbidity.

Authors' Conclusions

In prevention trials, early intervention with amniotomy and oxytocin appears to be associated with a modest reduction in the rate of caesarean section over standard care.

---

### ACOG committee opinion no. 597: committee on obstetric practice: labor induction or augmentation and autism [^71574740]. Obstetrics and Gynecology (2014). Low credibility.

Functional oxytocin deficiency and a faulty oxytocin signaling pathway have been observed in conjunction with autism spectrum disorder (ASD). Because exogenous synthetic oxytocin commonly is administered for labor induction and augmentation, some have hypothesized that synthetic oxytocin used for these purposes may alter fetal oxytocin receptors and predispose exposed offspring to ASD. However, current evidence does not identify a causal relationship between labor induction or augmentation in general, or oxytocin labor induction specifically, and autism or ASD. Recognizing the limitations of available study design, conflicting data, and the potential consequences of limiting labor induction and augmentation, the Committee on Obstetric Practice recommends against a change in current guidance regarding counseling and indications for and methods of labor induction and augmentation.

---

### Maximum dose rate of intrapartum oxytocin infusion and associated obstetric and perinatal outcomes [^4319becb]. Obstetrics and Gynecology (2023). Medium credibility.

Objective

Despite lack of evidence for a safety threshold for oxytocin dose rate, many hospital protocols specify a maximum rate. We investigated whether exceeding 20 milliunits/min of oxytocin was associated with adverse outcomes.

Methods

This is a secondary analysis of a double-blind, single-center, randomized controlled trial of nulliparous patients with singleton gestations at 36 weeks of gestation or later who presented in spontaneous labor randomized 1:1 to either a high-dose oxytocin titration regimen (initial-incremental rate of 6 milliunits/min) or standard-dose titration regimen (initial-incremental rate of 2 milliunits/min) for labor augmentation. A maximum oxytocin dose rate limit was not specified in the study protocol. For this secondary analysis, outcomes of participants who received oxytocin and exceeded a dose rate of 20 milliunits/min at any point in labor were compared with those whose rate remained at 20 milliunits/min or less. In addition, the cumulative proportions of labor and birth outcomes were calculated for each maximum dose rate of oxytocin reached among this study cohort.

Results

Of the 1,003 participants in the parent trial, 955 (95.2%) received oxytocin, as planned, and were included, with 190 (19.9%) exceeding a maximum dose rate of 20 milliunits/min. Those who exceeded 20 milliunits/min were older and were more likely to have rupture of membranes as their trial entry indication, have hypertensive disorders of pregnancy, receive intrapartum magnesium sulfate infusion, and receive oxytocin for longer. Those whose maximum rates exceeded 20 milliunits/min underwent cesarean delivery more frequently, but the majority (74%) still delivered vaginally. In multivariable analyses, there were no significant associations between maximum oxytocin dose rates greater than 20 milliunits/min and cesarean delivery (adjusted odds ratio [aOR] 1.57, 95% CI 1.00–2.46), peripartum infection (aOR 0.69, 95% CI 0.41–1.19), postpartum hemorrhage (aOR 1.37, 95% CI 0.70–2.71), or neonatal intensive care unit (NICU) admission (aOR 1.72, 95% CI 0.89–3.31). Although 85% of spontaneous vaginal deliveries occurred at maximum oxytocin dose rates of 20 milliunits/min or less, vaginal deliveries continued to occur at higher maximum dose rates. The cumulative proportions of NICU admissions and composite severe neonatal morbidity and mortality cases increased with increasing oxytocin dose rates even with maximum oxytocin dose rates at 20 milliunits/min or less.

Conclusion

In multivariable analyses, there are no significant differences in maternal or perinatal adverse outcomes based on exceeding 20 milliunits/min of oxytocin. These data suggest that oxytocin dosing should be individualized to each patient and not be based on arbitrary thresholds.

Clinical Trial Registration

ClinicalTrials.gov, NCT02487797.

---

### Amniotomy plus intravenous oxytocin for induction of labour [^73b43738]. The Cochrane Database of Systematic Reviews (2001). Low credibility.

Background

Induction of labour is a common obstetric intervention. Amniotomy alone for induction of labour is reviewed separately and oxytocin alone for induction of labour is being prepared for inclusion in The Cochrane Library. This review will address the use of the combination of these two methods for induction of labour in the third trimester. This is one of a series of reviews of methods of cervical ripening and labour induction using standardised methodology.

Objectives

To determine, from the best available evidence, the efficacy and safety of amniotomy and intravenous oxytocin for third trimester induction of labour.

Search Strategy

The Cochrane Pregnancy and Childbirth Group Trials Register, the Cochrane Controlled Trials Register and reference lists of articles were searched. Date of last search: May 2001.

Selection Criteria

The criteria for inclusion included the following: (1) clinical trials comparing amniotomy plus intravenous oxytocin used for third trimester cervical ripening or labour induction with placebo/no treatment or other methods listed above it on a predefined list of labour induction methods; (2) random allocation to the treatment or control group; (3) adequate allocation concealment; (4) violations of allocated management not sufficient to materially affect conclusions; (5) clinically meaningful outcome measures reported; (6) data available for analysis according to the random allocation; (7) missing data insufficient to materially affect the conclusions.

Data Collection and Analysis

Trial quality assessment and data extraction were done by both reviewers. A strategy was developed to deal with the large volume and complexity of trial data relating to labour induction. This involved a two-stage method of data extraction. The initial data extraction was done centrally, and incorporated into a series of primary reviews arranged by methods of induction of labour, following a standardised methodology. The data is to be extracted from the primary reviews into a series of secondary reviews, arranged by category of woman.

Main Results

Seventeen trials involving 2566 women were included. Amniotomy and intravenous oxytocin were found to result in fewer women being undelivered vaginally at 24 hours than amniotomy alone (relative risk (RR) 0.03, 95% confidence intervals (CI) 0.001–0.49). This finding was based on the results of a single study of 100 women. As regards secondary results amniotomy and intravenous oxytocin resulted in significantly fewer instrumental vaginal deliveries than placebo (RR 0.18, CI 0.05–0.58). Amniotomy and intravenous oxytocin resulted in more postpartum haemorrhage than vaginal prostaglandins (RR 5.5, CI 1.26–24.07). Significantly more women were also dissatisfied with amniotomy and intravenous oxytocin when compared with vaginal prostaglandins, RR 53, CI 3.32–846.51.

Reviewer's Conclusions

Data on the effectiveness and safety of amniotomy and intravenous oxytocin are lacking. No recommendations for clinical practice can be made on the basis of this review. Amniotomy and intravenous oxytocin is a combination of two methods of induction of labour and both methods are utilised in clinical practice. If their use is to be continued it is important to compare the effectiveness and safety of these methods, and to define under which clinical circumstances one may be preferable to another.

---

### High-vs low-dose oxytocin regimens for labor augmentation: a systematic review and meta-analysis [^f2d36bdc]. American Journal of Obstetrics & Gynecology MFM (2025). Medium credibility.

Objective

This study aimed to assess whether high- vs low-dose oxytocin regimens for labor augmentation are associated with differential risk of low Apgar score, neonatal acidosis, and other adverse labor outcomes.

Data Sources

We searched electronic databases (MEDLINE, Embase, the Cochrane Library, CINAHL, Scopus, ClinicalTrials.gov) from inception up to March 2024 using combinations of the following key words: "oxytocin", "oxytocin regimen", "oxytocin protocol", "oxytocin dosage", "active management", "high dose protocol", "low dose protocol", and "augmentation of labor".

Study Eligibility Criteria

We included quasi-randomized and randomized controlled trials comparing continuous oxytocin infusion with high-dose regimens (intervention group) vs low-dose regimens (control group) in nulliparous or multiparous patients undergoing labor augmentation. High-dose regimens were defined as a starting oxytocin dose of ≥ 4 mU/min, increasing in increments of 3 to 7 mU/min every 15 to 40 minutes. Low-dose regimens were defined as a starting oxytocin dose of < 4 mU/min, increasing in increments of 1 to 2 mU/min every 15 to 40 minutes (PROSPERO CRD42024500197).

Methods

The coprimary outcomes were incidence of Apgar score < 7 at 5 minutes and umbilical arterial pH < 7.00. The secondary outcomes included cesarean delivery and chorioamnionitis. We performed random-effects head-to-head meta-analyses to compare high-dose with low-dose strategies, and reported summary risk ratios with 95% confidence intervals.

Results

Ten randomized and quasi-randomized controlled trials of 5508 pregnancies met the inclusion criteria and were included in this meta-analysis. There was no difference in risk for the coprimary outcomes of Apgar score < 7 at 5 minutes (relative risk, 0.94; 95% confidence interval, 0.60–1.46) and umbilical arterial pH < 7.00 (relative risk, 0.77; 95% confidence interval, 0.50–1.20). There was also no difference in risk for cesarean delivery (relative risk, 0.83; 95% confidence interval, 0.67–1.02). High-dose oxytocin regimens were associated with significantly lower risk of chorioamnionitis (relative risk, 0.70; 95% confidence interval, 0.57–0.84; number needed to treat = 25) and higher risk of tachysystole (relative risk, 1.32; 95% confidence interval, 1.21–1.43; P < .001).

Conclusion

When used for labor augmentation, high-dose oxytocin regimens decreased the risk of chorioamnionitis compared with low-dose regimens without affecting the risk of low Apgar scores, neonatal acidosis, or cesarean delivery. El resumen está disponible en Español al final del artículo.

---

### First and second stage labor management: ACOG clinical practice guideline no. 8 [^359efddd]. Obstetrics and Gynecology (2024). High credibility.

Early oxytocin augmentation for protraction or arrest — Early oxytocin was associated with a modest increase in spontaneous vaginal delivery (RR 1.09; 95% CI, 1.03–1.17), with one additional spontaneous vaginal delivery per 20 patients treated. Antibiotic use decreased (RR 0.45; 95% CI, 0.21–0.99) but uterine hyperstimulation/tachysystole increased (RR 2.90; 95% CI, 1.21–6.94), without evidence of adverse neonatal effects. A follow-up review found reduced cesarean births (11 trials; n = 7,753) (RR 0.87; 95% CI, 0.77–0.99). Early oxytocin with early amniotomy shortened labor (eight trials, n = 4,816 patients) (average MD −1.28 hours; 95% CI, −1.97 to −0.59) with no significant effects on maternal or neonatal morbidities, and an AHRQ review similarly concluded shorter labor duration without effect on overall cesarean rate versus delayed oxytocin.

---

### Venlafaxine tablet, extended release… [^c6c39601]. FDA (DailyMed) (2021). Medium credibility.

Efficacy of venlafaxine extended-release in the treatment of SAD was established in short-term SAD trials. 2 DOSAGE AND ADMINISTRATION Venlafaxine extended-release tablets should be administered in a single dose with food either in the morning or in the evening at approximately the same time each day. Each tablet should be swallowed whole with fluid and not divided, crushed, chewed, or placed in water. Based on these limited data, it is not known whether or not the dose of venlafaxine extended-release tablets needed for maintenance treatment is identical to the dose needed to achieve an initial response. Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment.

Patients with Hepatic Impairment Given the decrease in clearance and increase in elimination half-life for both venlafaxine and ODV that is observed in patients with hepatic cirrhosis and mild and moderate hepatic impairment compared with normal subjects, it is recommended that the total daily dose be reduced by 50% in patients with mild to moderate hepatic impairment. Since there was much individual variability in clearance between patients with cirrhosis, it may be necessary to reduce the dose even more than 50%, and individualization of dosing may be desirable in some patients. Patients with Renal Impairment Given the decrease in clearance for venlafaxine and the increase in elimination half-life for both venlafaxine and ODV that is observed in patients with renal impairment compared with normal subjects, it is recommended that the total daily dose be reduced by 25% to 50%. In some cases, a patient already receiving venlafaxine extended-release tablets therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, venlafaxine extended-release tablets should be stopped promptly, and linezolid or intravenous methylene blue can be administered. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt.

---

### Obstetric care consensus # 10: management of Stillbirth: (replaces practice bulletin number 102, March 2009) [^26c36766]. American Journal of Obstetrics and Gynecology (2020). High credibility.

Induction regimens by gestational age — Before 28 weeks of gestation, vaginal misoprostol appears to be the most efficient method of induction, although high-dose oxytocin infusion also is an acceptable choice. A meta-analysis of 14 randomized controlled trials demonstrated that both vaginal and oral misoprostol regimens were 100% effective in achieving uterine evacuation within 48 hours. Based on limited evidence, before 28 weeks of gestation, typical dosages for misoprostol are 400–600 μg vaginally every 3–6 hours, and doses less than 400 μg have decreased efficacy. After 28 weeks of gestation, induction of labor should be managed according to usual obstetric protocols.

---

### First and second stage labor management: ACOG clinical practice guideline no. 8 [^faafe5fb]. Obstetrics and Gynecology (2024). High credibility.

Labor and labor arrest — ACOG Clinical Practice Guideline No. 8 recommendations state that ACOG recommends that cervical dilation of 6 cm be considered the start of the active phase of labor (STRONG RECOMMENDATION, MODERATE-QUALITY EVIDENCE). ACOG suggests that active phase arrest of labor be defined as no progression in cervical dilation in patients who are at least 6-cm dilated with rupture of membranes despite 4 hours of adequate uterine activity or 6 hours of inadequate uterine activity with oxytocin augmentation (CONDITIONAL RECOMMENDATION, LOW-QUALITY EVIDENCE). ACOG recommends that prolonged second stage of labor be defined as more than 3 hours of pushing in nulliparous individuals and 2 hours of pushing in multiparous individuals (STRONG RECOMMENDATION, HIGH-QUALITY EVIDENCE). An individualized approach should be used to diagnose second-stage arrest; incorporating information regarding progress, clinical factors that may affect the likelihood of vaginal delivery, discussion of risks and benefits of available interventions, and individual patient preference is recommended when time in the second stage is extended beyond these parameters. Arrest in the second stage can be identified earlier if there is lack of fetal rotation or descent despite adequate contractions, pushing efforts, and time (GOOD PRACTICE POINT). ACOG recommends that neuraxial anesthesia be offered for pain relief during any stage of labor (STRONG RECOMMENDATION, MODERATE-QUALITY EVIDENCE).

---

### Clinical guidelines. labor induction abortion in the second trimester [^2c5df3f5]. Contraception (2011). Low credibility.

Labor induction abortion is effective throughout the second trimester. Patterns of use and gestational age limits vary by locality. Earlier gestations (typically 12 to 20 weeks) have shorter abortion times than later gestational ages, but differences in complication rates within the second trimester according to gestational age have not been demonstrated. The combination of mifepristone and misoprostol is the most effective and fastest regimen. Typically, mifepristone 200 mg is followed by use of misoprostol 24–48 h later. Ninety-five percent of abortions are complete within 24 h of misoprostol administration. Compared with misoprostol alone, the combined regimen results in a clinically significant reduction of 40% to 50% in time to abortion and can be used at all gestational ages. However, mifepristone is not widely available. Accordingly, prostaglandin analogues without mifepristone (most commonly misoprostol or gemeprost) or high-dose oxytocin are used. Misoprostol is more widely used because it is inexpensive and stable at room temperature. Misoprostol alone is best used vaginally or sublingually, and doses of 400 mcg are generally superior to 200 mcg or less. Dosing every 3 h is superior to less frequent dosing, although intervals of up to 12 h are effective when using higher doses (600 or 800 mcg) of misoprostol. Abortion rates at 24 h are approximately 80%-85%. Although gemeprost has similar outcomes as compared to misoprostol, it has higher cost, requires refrigeration, and can only be used vaginally. High-dose oxytocin can be used in circumstances when prostaglandins are not available or are contraindicated. Osmotic dilators do not shorten induction times when inserted at the same time as misoprostol; however, their use prior to induction using misoprostol has not been studied. Preprocedure-induced fetal demise has not been studied systematically for possible effects on time to abortion. While isolated case reports and retrospective reviews document uterine rupture during second-trimester induction with misoprostol, the magnitude of the risk is not known. The relationship of individual uterotonic agents to uterine rupture is not clear. Based on existing evidence, the Society of Family Planning recommends that, when labor induction abortion is performed in the second trimester, combined use of mifepristone and misoprostol is the ideal regimen to effect abortion quickly and completely. The Society of Family Planning further recommends that alternative regimens, primarily misoprostol alone, should only be used when mifepristone is not available.

---